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Abstract  
Purpose: It has been reported that over 33 % of patients with OAB present with pyuria (≥10 
wbc µl-1) on urine microscopy, but under a third of these have bacteriuria. To clarify this 
situation, an accomplished comparative scrutiny of the inflammatory state of the urothelium 
in OAB, was carried out. 
 
Materials and Methods: This was a prospective, blinded, observational study of idiopathic 
OAB patients compared with controls. CSU samples were obtained and submitted to fresh 
urine microscopy, routine culture and microscopic examination of  spun sediment. Another 
sample of OAB patients and asymptomatic controls provided cystoscopic bladder biopsies for 
histopathology and electron microscopy.  
 
Results: 178 OAB patients and 21 controls provided spun sediment samples. 75 (42 %) of 
these OAB patients had microscopic pyuria (≥1 wbc µl-1) with 25 of which (33 %) were 
culture-positive. None of the controls had pyuria, nor bacteriuria. In a 20 mm
2
 spun deposit 
there was an average of 48 wbc (95 % CI 26 to 589) in OAB with pyuria; 12 wbc (95 % CI 
10 to 15) in OAB without pyuria; and 4 wbc (95 % CI 3 to 7) in controls. Biopsies from 79 
OAB patients, showed chronic inflammation and hyperplasia in 69 (87 %; 95 % CI=78 to 92: 
only 20 % had pyuria) and none in 5 controls. EM of 22 OAB patients showed increased 
basement membrane thickness compared to 2 controls (H=48, df=2, p<0.001) 
 
Conclusions: The study shows evidence of chronic cystitis and urothelial hyperplasia 
associated with OAB irrespective of pyuria or bacteriuria. The phenomenon has been 
confirmed by 3 different methods. 
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CHAPTER 1 
 
LOWER URINARY TRACT SYMPTOMS 
 
The term lower urinary tract symptoms (LUTS) describe storage, voiding, and post 
micturition symptoms. According to two recent multinational population-based studies, the 
prevalence of LUTS is 3–10 % in men aged 40–49 years, rising to 24–29 % in those aged 70–
80 years (1),(2). Problems with storage are commoner (men, 51 %; women, 59 %) than 
voiding difficulties (men, 25 %; women, 19 %). Both sexes are similarly affected by post 
micturition symptoms (men, 17 %; women, 14 %). The prevalence of overactive bladder 
(OAB) causing frequency, urgency and/or incontinence is 11 %. All these symptoms are 
more common in late life (2). Chronic prostatitis (CP), also called “Chronic pelvic pain 
syndrome” (CPPS) has a 9 % prevalence in men (3). Interstitial Cystitis (IC) also called 
“Painful bladder syndrome (PBS) occurs in between 5 and 16 per 100,000 (4). 
Symptomatically, all these conditions overlap substantially and clear diagnostic 
compartmentalization is very difficult (5). 
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1.1   Overactive bladder 
1.1.1  What is it? 
The International Continence Society (ICS) defines Overactive Bladder (OAB) as “Urgency, 
with or without urge incontinence, usually with frequency and nocturia” with the synonyms 
the overactive bladder syndrome, urge syndrome or urgency-frequency syndrome. These 
terms may be used provided that there is “no proven infection or obvious pathology” (6). 
“OAB-dry” is a term that describes individuals with symptoms of OAB but without urge 
incontinence. Similarly “OAB-wet” is a term that describes individuals with symptoms of 
OAB with urge incontinence. The key symptom of OAB is urgency - the sudden, compelling 
desire to void that is difficult to defer.
 
Frequency is defined as the patient complaining of 
voiding 8 times or more in a day, and nocturia is the complaint that the individual wakes up 
more than once at night to void. Frequency and nocturia can occur with or without urge 
incontinence (7;8). Urinary incontinence is the complaint of any involuntary leakage of urine. 
Urge incontinence is the involuntary loss of urine accompanied by or immediately preceded 
by urgency (6). A debate persists about the appropriateness of the term OAB as some doubt 
whether it is really a syndrome, particularly because the symptoms frequency, urgency and 
urge incontinence do not imply a single disease. In point of fact they are symptoms of several 
different pathological states which includes; detrusor overactivity, detrusor hypersensitivity, 
infravesical obstruction, bladder neck insufficiency and polyuria (7). 
 
Cystitis is left off this list because it is always accepted that diagnosis has been excluded, 
assuming the accuracy of the tests used to achieve this. 
 
The symptoms of OAB are usually attributed to involuntary contractions of the detrusor 
muscle (9). Detrusor overactivity; whether neurogenic (arising from neuropathology); 
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myogenic (arising from detrusor muscle disease); or idiopathic (no known cause), is 
characterized by involuntary contractions of the detrusor during the filling phase that may be 
spontaneous or provoked. Involuntary detrusor contractions may occur at any bladder volume. 
The ICS describes 2 types of detrusor overactivity: phasic and terminal. Phasic detrusor 
overactivity is defined by a characteristic waveform and may or may not lead to urinary 
incontinence; it is the pattern typically seen in most idiopathic detrusor overactivity. Terminal 
detrusor overactivity is characterized by a single involuntary detrusor contraction that occurs 
at cystometric capacity (when the normal, controllable desire to void is experienced), which 
cannot be suppressed and results in incontinence, often leading to complete bladder emptying 
(6).  
 
1.1.2  Anatomy of  Lower  urinary  Tract 
The lower urinary tract consists of the urinary bladder, the urethra, the internal urinary 
sphincter, the bladder outlet, the external urethral sphincter, and the striated muscles of the 
pelvic floor. The structures of the pelvic floor are similar in males and females; however, in 
males, the bladder neck is stronger and the prostate and rhabdosphincter offer support. In 
females, the levator ani muscles and the external sphincter are the primary bladder support 
structures (10). The bladder wall is lined with bundles of smooth muscle fibers that make up 
the detrusor bulk. The fibers are interspersed with connective tissue, giving the bladder its 
compliance – which describes the relationship between change in bladder volume and change 
in detrusor pressure. The internal urinary sphincter consists of the bladder neck and the 
proximal urethra itself. The urethra and the entire internal urinary sphincter are surrounded by 
striated muscle fibers. The bladder outlet consists of the internal sphincter and its surrounding 
striated musculature and is supported by the pelvic floor muscles (10;11). The periurethral 
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striated muscle fibers and those surrounding the entire internal sphincter constitute the 
external urethral sphincter. 
 
1.1.3  Innervation 
The lower urinary tract is innervated by an integrated afferent and efferent neuronal complex 
of peripheral neural circuits involving sympathetic, parasympathetic, and somatic neurons 
(12). The efferent pathways are heavily myelinated, whereas the bladder afferent pathways 
consist of myelinated A-δ fibers and unmyelinated C-fibers. The normal micturition reflex is 
initiated by signals from the A-δ fibers; the C-fibre afferent neuron signals are not essential 
for normal voluntary voiding (13). 
 
The sympathetic nerves arise in the lateral horns of spinal segments T1–L2. These 
preganglionic fibers branch off and enter the sympathetic ganglia. The sympathetic nervous 
system stimulates sphincter closure in the urethra as well as relaxation of the detrusor muscle 
during filling (10). Conversely, the parasympathetic nervous system is responsible for the 
contraction of the detrusor muscle during micturition while simultaneously relaxing the 
urethral sphincter. Parasympathetic innervation arises from the 2
nd
, 3
rd
, 4
th
 sacral segments of 
the spinal cord. 
 
The somatic efferent motor neurons arise from the 2
nd
, 3
rd
, 4
th
 segments of the sacral spinal 
cord. Somatic innervation maintains tone in the pelvic floor musculature and provides 
excitatory innervation to the striated muscles of the external urethral sphincter. Bladder 
control also comes from the higher centres, including the brain stem and cerebral cortex. The 
cortex exerts a predominantly inhibitory influence, while the influence of the brain stem is 
facilitatory. 
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1.1.4  Neurotransmission 
Acetylcholine activation of muscarinic receptors to stimulate contraction of the detrusor 
appears to be the most important physiologic control system for urinary bladder contraction 
(9;14;15). Muscarinic receptors, found on presynaptic nerve terminals, may be excitatory or 
inhibitory. There are atleast 5 types of muscarinic receptors but to date, ≥3 muscarinic 
receptor subtypes (M1 to M3) have been identified in the human bladder by receptor-binding 
assays (15). Very small numbers of M1 receptors appear to facilitate the release of 
acetylcholine in the bladder (16). M2 receptors predominate numerically in the human 
bladder, but M3 receptors mediate the cholinergic-induced contractions of the detrusor (15). It 
seems that the M2 and M3 receptors are functionally coupled and act synergistically (17;18). 
Activation of M2 receptors inhibits sympathetically mediated detrusor relaxation; therefore, 
coactivation of M2 receptors may enhance the detrusor contraction in response to M3 receptor 
activation (12). There is some evidence that M2 receptors may also partially stimulate bladder 
contraction directly (18). The relative contribution of the different muscarinic receptors may 
be altered during aging, disease, or neurogenic lesions; muscarinic receptor functions may 
upregulate mechanisms that normally have little clinical importance, and contribute to the 
pathophysiology of OAB (16). 
 
The sympathetic nervous system also contributes through the influence of a noradrenergic 
innervation (19).   
 
For many years it has been recognised that there is also some non-adrenergic, non-cholinergic 
(NANC) innervation of the bladder (20;21).This has been identified as mediated via the 
influence of ATP acting on purinergic receptors (22). NANC transmission has been 
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particularly described in animal models and it was thought to contribute very marginally to 
human bladder function, which may not be the case in pathological states.  
 
1.1.5  The History of NANC Transmission 
Burnstock et al. in 1962 recorded inhibitory junctional transmission between enteric neurones 
and smooth muscle cells of the gut. These inhibitory junction potentials (IJPs) were first 
attributed to stimulation of sympathetic nerve terminals releasing noradrenaline. The 
discovery that the IJP could not be blocked with the adrenergic blocking drugs, that this 
transmission was identified as nonadrenergic and noncholinergic, hence introduction of the 
acronym NANC. At the same time that NANC inhibitory junctional transmission was 
described, an atropine-resistant excitatory junctional potential (EJP) to the same smooth 
muscle of the gut was discovered and so that an excitatory NANC transmission was identified. 
Much work has gone into to identify the NANC transmitters responsible for these properties. 
In the gut the IJP has been found to arise from nitric oxide signaling and the EJP result from 
tachykinins. Burnstock et al. has always promoted the view that purines are important 
transmitters for the EJP in many of the pelvic viscera and blood vessels. The nerves that use 
ATP as the principal transmitter were named 'purinergic'. It was Burnstock who proposed a 
model of storage, release, and inactivation of ATP (22) and this has indeed been supported by 
subsequent experimental data (23;24) despite initial opposition to the idea. Understandably 
biochemists saw ATP as an intracellular energy source and balked at the idea that this could 
be used for inter-cellular signaling as well. This stands true to the Darwin theory of evolution 
about grabbing a remarkable opportunity. ATP was one of the 1
st
 biological molecules to 
appear and, so it is very reasonable that it has been co-opted for extracellular and intracellular 
purposes by evolution (25).  
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1.1.5.1 NANC Transmitters 
A large number of NANC transmitters are recognized and the 3 important classes are - 
Neuropeptides (e.g. Angiotensin, Opioids), Purines (e.g. ATP, Adenosine, ADP, and AMP) 
and NO (Nitric oxide). Nitric oxide is unique in being produced on demand. It is not pre-
stored in vesicles. 
 
1.1.5.2 Purinergic Receptors 
2 main types of purinoceptor have been identified as P1 for adenosine and P2 for ATP/ADP 
(26) (27). In both cases, sub-groups of these classes have been identified (28).
 
In 1985 a 
pharmacological properties were used to distinguish 2, P2 receptors P2X and P2Y (26). In 
1994, Abbracchio and Burnstock, following signal transduction experiments and molecular 
biological sequencing proposed that purinoceptors should be divided into 2 families: a P2X 
family of ligand-gated ion channel receptors and a P2Y family of G-protein-coupled 
receptors. This has been widely adopted and nowadays 7, P2X subtypes and 8, P2Y receptor 
subtypes are recognized. These now include some receptors responsive to pyrimidines as well 
as purines (28) (29). 4 subtypes of P1 G-protein-coupled receptors have been cloned, namely, 
A1, A2A, A2B, and A3. 7 subtypes of P2X receptors have been identified. The P2X subunit 
class occurs in 2 different size clusters, one about 1 μm diameter and the other about 0.4 μm 
diameter all smooth muscle studied to date, including the urinary bladder (30). The subunits 
P2X2, P2X3, and P2X5 are commonly found in clusters in the detrusor, but fewer P2X4 and 
P2X6 (31). 
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1.1.6  Co-Transmission 
Burnstock et al (32) proposed the cotransmitter hypothesis.  By this he meant that nerve 
terminals could produce more than one neurotransmitter. Nowadays it is accepted that many 
nerves signal via more than one molecule. ATP is a cotransmitter with classical transmitters 
(ACh and NA) in most nerves of the peripheral (PNS) and central nervous systems (CNS) 
(33).  Parasympathetic nerves supplying the urinary bladder use ACh
 
and ATP as 
cotransmitters, in variable proportions in different
 
species (27;34).  
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1.2   Pathophysiology of OAB 
 
An understanding of the pathophysiology of OAB should assist effective treatment. Normal 
urinary storage and voiding function depends on interactions between the cerebral cortex, 
pons, spinal cord and autonomic nervous system. There is scope for many different 
pathological processes to affect the nervous control and tissue function of the system at 
numerous locations (9;10;35). 
 
OAB may be classified according to the presumed aetiology of the lesion: neurogenic (e.g., 
spinal cord injury), myogenic (e.g., obstruction secondary to benign prostatic hyperplasia), 
inflammatory (e.g., interstitial cystitis), or idiopathic. (36). 
 
Regardless of the underlying disease, OAB manifests some typical behaviour. These include 
spontaneous intravesical pressure rises during bladder filling, spontaneous contractions of 
organ-bath mounted detrusor, a tendency to fused tetanic contractions, and alterations in 
sensitivity to neurotransmitters.  
 
1.2.1  Electrical properties of the detrusor 
The spontaneous contractions occurring in isolated detrusor strips been documented in tissue 
from obstructed unstable bladders (37) and neuropathic bladder (38). It has been observed 
that in response to obstruction there is increased sensitivity to muscarinic stimulation and to 
potassium chloride, but have reduced contraction to tetrototoxin (TTX) sensitive electrical 
stimulation (39)(40). In idiopathic overactivity, isolated strips show increased responsiveness 
to potassium chloride but not cholinergic stimulation. However, reduced contraction to 
tetrototoxin (TTX) sensitive electrical stimulation is also shown (41). If denervated, detrusor 
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will express increased quantities of M3 receptors (42).The smooth muscle bundles of the 
detrusor rely on dense innervations in order to achieve synchronous contractions through 
simultaneous stimulation. Whereas, overactive bladder may exhibit increased cell-to-cell 
coupling i.e better coupled electrically. This generates uninhibited contractions. Given the 
dense neuronal innervation of the cells it is difficult to be confident that it will contribute 
significantly to the disease process (43).  
 
1.2.2  Morphologic changes in the detrusor 
There have been a limited number of histological studies of bladder obtained from patients 
with OAB. The morphological changes described include patchy denervation, hypertrophy 
and fibrosis (44). 1 study has reported at an ultrastructural changes but further experiments 
failed to reproduce these findings (45). 
 
1.2.3  Neuroplasticity 
It has been found that the nervous system is capable of changing neurotransmitters, reflexes, 
and synapse function in response to disease. This is now referred to as neuroplasticity. This 
has been invoked to explain some of the pathological responses that are exhibited by the 
bladder (46). This particularly seems to involve the enhancement of ATP activity. The 
significance of these changes mean that in diseased states a different set of neuroactive drugs 
would be required to modify function than those implied through studies of the health state. 
 
1.2.4  Ischaemic changes  
The symptoms of OAB amongst the elderly are associated with reduced bladder capacity, 
slower voiding and incomplete bladder emptying. Recently these manifestations have been 
induced in animal models by the induction of bladder ischaemia (47). 
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It has been found the nerves are more susceptible to ischaemic damage than is the detrusor. It 
is notable that the patterns of bladder overactivity measured in the elderly have been found to 
parallel those identified in younger patients with neurological disease (48). 
 
1.2.5  Central nervous system 
Spinal cord transection results in detrusor hyperreflexia. This features highly reproducible 
reflex bladder contractions that can be induced reliably by the infusion of the same volume of 
saline into a bladder. Cord transection is also associated with urinary retention arising from 
detrusor sphincter dyssynergia and a reduced ability to sustain a detrusor contraction (49-51). 
After spinal injury, there is some delay before the micturition reflex re-establishes and during 
this period there is complete urinary retention (52;53)(46). With time the micturition pathway 
is reorganized forming a spino-bulbo-spinal or spinal loop, which dominates the life of the 
bladder through primitive reflex voiding. It is notable that C-fiber (unmyelinated) afferents in 
particular can trigger micturition contractions in the spinal bladder, whereas this is not a 
feature of normal bladders (54;55). 
 
1.2.6  The urothelium 
Nowadays it is becoming evident that the urothelium plays a more active role in bladder 
physiology than a simple barrier. The urothelium is able to communicate with afferents on 
the basal surface that would seem to convey important signals related to bladder filling. 
Urothelium releases Ach, NO, but a development of considerable significance is the 
recognition that the human urothelium can generate ATP, which acts on suburothelial 
purinergic afferents. For a long time it was assumed that the human bladder produced very 
little ATP and this is probably the case in normal circumstances, However in the presence of 
inflammation there is a considerable potential for a great enhancement of ATP production in 
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response to urothelial stretch and if this were to be shown to be the case it would greatly alter 
the current appreciation of the bladder pathophysiology (56). 
 
1.2.7  Other factors 
There have been a plethora of hypotheses about the pathophysiology of OAB that have 
implicated in various ways i.e. nerve growth factor, local tissue acidosis, hyperkalaemia, 
hyperosmolality, neurotrophins and cytokines. Much of this is drawn from animal models and 
there is a regrettable lack of human data. Perhaps this problem could be alleviated by greater 
use of the human tissue samples that are available from different sources, including the urine 
and flexible cystoscopic biopsies. Given the advances in scientific methods it may be that 
these previously limited options may prove to be capable of narrating a more sophisticated 
tale.     
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1.3   Epidemiology 
LUTS describes storage, voiding, postmicturition and pain symptoms. According to 2 recent 
multinational population-based studies, the prevalence of LUTS is 3–10 % in men aged 40–
49 years, rising to 24–29 % in those aged 70–80 years (1;57;58). Problems with storage are 
commoner (men, 51 %; women, 59 %) than voiding difficulties (men, 25 %; women, 19 %). 
Both sexes are similarly affected by postmicturition symptoms (men, 17 %; women, 14 %). 
The prevalence of overactive bladder (OAB) causing frequency, urgency and/or incontinence 
is 11 %. All these symptoms are more common in later life (2). Chronic prostatitis (CP), also 
called “Chronic pelvic pain syndrome” (CPPS) has a 9 % prevalence in men (3). Interstitial 
Cystitis (IC) also called “Painful bladder syndrome (PBS) occurs in between 5 and 16 per 
100,000 adults (4). Symptomatically, all these conditions overlap considerably and their 
pathophysiology is not clear (5). The burden is illustrated by OAB, the commonest, which is 
independently associated with falls and fractures; urinary tract and skin infections; sleep 
disturbances and depression. A survey of 16,776 interviews, conducted in 6 European 
countries, found a prevalence of overactive bladder symptoms of 16.6 % in individuals aged 
≥ 40 years. Frequency (85 %) was the most commonly reported symptom, followed by 
urgency (54 %) and urge incontinence (36 %). The prevalence of OAB increased with 
advancing age (59). These symptoms overlap with those experienced in urinary infection 
(UTI), “frequency-urgency-dysuria”, “Painful bladder syndrome” and “Interstitial cystitis”. 
The latter has an estimated prevalence of 0.31 %; 94 % female (Kidney and Urologic 
Diseases Statistics USA, 1988-1994). The lifetime risk of UTI for women is between 40 % 
and 60 %, and recurrent UTI occurs in 16 to 40 % of women who have had 1 UTI.  In some, 
recurrent UTI is a serious problem (60). 
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One study has estimated that OAB cost 5 EEC countries in excess of €4.2 billion in the year 
2000 (61). Urinary tract infection is one of the commonest infectious diseases worldwide (62). 
Below is a table reproduced with permission from a New England Journal of Medicine 
review written by J.Ouslander (2004) (9). 
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1.4   Conditions that may cause or contribute to symptoms of  
  OAB? 
                         Displayed with permission - from JG Ouslander (9) 
 
Conditions Mechanism or Effect Implications for management 
Lower urinary tract conditions –  
        Both sexes 
Urinary Tract Infection Inflammation/activation 
of sensory afferent 
Treat infection before other 
interventions are considered 
Obstruction Can contribute to detrusor 
overactivity or urinary 
retention 
Consider surgical intervention 
Impaired bladder 
contractility 
Reduced functional bladder 
capacity 
Avoid drugs contributing, teach 
to enhance voiding, clean 
Intermittent catheterization may 
be helpful 
Bladder abnormalities  
(tumor/stone/ interstitial 
cystitis) 
Can precipitate Detrusor 
overactivity 
Sterile haematuria/risk factors 
shall be evaluated 
       Women 
Estrogen deficiency Atrophic vaginitis / 
Urethritis can contribute to 
symptoms 
Topical estrogen may help 
Sphincter weakness Leakage of urine  into 
proximal urethra may 
precipitate urgency 
Pelvic musc, periurethral 
injections or surgery needed 
        Men 
 
Prostate enlargement Benign or malignant disease 
can contribute to detrusor 
overactivity 
Screen for prostate cancer, 
consider Alpha blocker, 5-alpha 
reductase inhibitor or surgery 
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Neurologic conditions 
 
Brain – stroke, dementia, 
Alzheimer’s, Parkinson’s, 
multiple sclerosis 
neurogenic detrusor 
overactivity 
Management include means of 
compensation for impaired 
cognition or mobility, or both 
Spinal cord – lumbar 
stenosis, disc herniation, 
spinal cord injury, 
multiple sclerosis 
neurogenic detrusor 
overactivity / urinary 
retention 
Necessary evaluation +/- 
Urodynamic testing deemed 
necessary 
Peripheral innervation –  
diabetic neuropathy, nerve 
injury 
Low functional bladder 
capacity / urinary retention 
Further evaluation for nerve 
injury. 
Systemic conditions 
 
Heart failure, venous 
insufficiency 
Volume overload can cause 
increase frequency and 
nocturia 
Timing of diuretics, salt 
restriction 
Diabetes mellitus Osmotic diuresis and 
polyuria 
Good blood glucose control 
Sleep disorders Can cause nocturia Further evaluation 
Abnormalities of arginine 
vasopressin 
Can cause Polyuria and 
nocturia 
May benefit from desmopressin 
therapy 
Functional and behavioral conditions 
 
Excess intake of caffeine / 
alcohol 
Polyuria and urinary 
frequency can result 
Modification of fluid intake is 
critical 
Poor bowel habits / 
constipation 
Fecal impaction may 
contribute to symptoms 
Appropriate bowel regime 
Impaired mobility Interfere with toileting 
ability and precipitate urge 
incontinence 
Treating underlying disorder 
including physical therapy 
Psychological conditions Anxiety / voiding 
dysfunction can cause 
Further evaluation 
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symptoms 
Side effects of medication 
 
Diuretics Causes rapid increase in 
bladder volume 
Altering the timing of dose or 
changing the diuretics 
Narcotics, calcium 
channel blockers 
Affects bladder contractility 
and capacity 
Consider discontinuation if 
feasible 
Cholinesterase inhibitors Can contribute to detrusor 
overactivity 
No clinical studies as yet 
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1.5   Diagnostic Evaluation 
Effective treatment of patients depends on an accurate evaluation. Nowadays there are 
guidelines
 
for the management of urinary incontinence (63) and benign prostatic
 
hyperplasia 
(64). Clearly, the clinical history is all-important and it is common place for disease-specific 
symptom questionnaires to be deployed. The International Prostate Specific Symptom Score 
(IPSS) is recommended by the American
 
Urological Association (AUA) and the European 
Association of Urologists (EAU) (65;66). There are a variety of questionnaires addressing the 
broader lower urinary tract symptoms and these are now being consolidated by the 
International Consultation on Incontinence (ICI), this work being supported by a bespoke 
website (http://www.iciq.net/). A desire to measure urgency so as to detect between treatment 
groups differences in change prompted the development of a particularly sensitive 
measurement scale for urgency by Al-Buheissi et al. (67;68). Bladder diaries are also 
recommended to describe the frequency, volume, and daily rhythm of
 
voiding (69;70). The 
texts recommend a detailed physical examination that includes genitourinary, pelvic, and
 
rectal examinations although the evidence that, in the absence of leading symptoms, such 
invasive assessment provide important data is lacking. For the sake of the patients, the 
underlying assumptions merit critical testing.  
 
Tests to exclude infection form an important part of the assessment. The science related to 
these methods is covered in the next section. 
 
 
Chronic urinary retention should be checked for in patients at specific risk of this; such 
advice would apply to diabetics,
 
spinal injury sufferers, persons with MS, benign prostatic 
enlargement and some elderly. This
 
can be accomplished by sterile residual catheterization 
with a Jacques catheter. There are some portable ultrasonographic devices for non-invasive
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identification of clinically significant residual urine (>100
 
ml). The latter term “clinically 
significant residual urine” brings into focus another conundrum. The relief of incomplete 
bladder emptying, by intermittent catheterisation or surgery, evinces good evidence of benefit 
for patients with neurological disease, men with prostatic obstruction and following Botox 
injections. In other circumstances there are no data to justify a threshold of a significant 
residual of ≥100 ml nor is the evidence that treating such residuals convincing. In some cases 
we do not know which is causative, the infection or the retention. The EAU guidelines accept 
an untreated residual of up to 350 ml (71). Despite this conundrum it has been accepted that 
any residual urine volume is only significant if it is symptomatic. 
 
Patients with haematuria on dipstick merit this being checked by microscopy since the 
dipsticks are very sensitive. Patients with haematuria associated with urinary infection should 
be followed up after resolution of the infection. Persistent haematuria, identified by 
microscopy and without proteinuria merits screening for bladder cancer. Based on the risk 
factors identified, urine cytology, imaging and cystoscopy may be indicated.  
 
The EAU Guidelines recommend Cystoscopy for patients with a history of recurrent urinary 
tract
 
infection. It has been claimed that cystoscopy should be offered to all patients with 
overactive bladder symptoms. The literature lacks a clear explanation of what the 
cystoscopist should be looking for. Additionally there is a lack of data on the sensitivity and 
specificity of cystoscopy in these circumstances. If the majority of examinations are negative, 
the positive predictive value will be extremely low and weak specificity will drive up 
management costs and add to patient distress. 
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It is possible that a young man could present with LUTS, or even OAB symptoms. Possibility 
should not be confused with probability. In the absence of evidence, it should be remembered 
that rarity
 
will push down the positive predictive value and specificity of a PSA will generate 
adverse repercussions. 
 
The role of urodynamic testing in the evaluation of patients with OAB symptoms has been 
questioned (72). The evidence implies that symptoms are the key to diagnosis. It has to be 
said the investigation of other LUTS by urodynamics has a very meager fund of evidence 
(73). As far as OAB symptoms are concerned, none of modern guidelines recommend 
urodynamics as part of the primary assessment. But, Urodynamics does have a role in clinical 
practice after primary assessment and treatment failure. 
 
It is germane that the evidence in support of the tests to rule out infection in this situation is 
no less threadbare (74-77).  
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1.6   Care Pathways for Management of Incontinence 
 
The cost of treating urinary incontinence in UK, community-dwelling adults, aged over 40 
was estimated as £536 million in 1999/2000 prices with cost to the individuals of £207 
million (78). There is considerable interest in reducing these sums. One option, that has been 
vociferously promoted, has been the use of structured pathways of care. 
 
“Integrated Care Pathways” (ICP), synonymous with “Clinical Pathways” (CP), were 
introduced in the UK and the USA during the early 1990’s. They are being increasingly 
adopted throughout the developed world. ICP’s are structured, multi-disciplinary plans of 
care designed to support the implementation of clinical guidelines and protocols. They are 
supposed to improve clinical, resource and risk management whilst enhancing clinical 
effectiveness, audit and financial control. The pathways provide detailed guidance for each 
stage in the management of a patient with a specific condition, and include measures of 
progress and outcome.  
 
Pathways have been designed for over 45 conditions and one of those is urinary incontinence. 
There are several proposals in the literature and some are also designed under the sponsorship 
of the NHS Research and Development of the Health Technology Assessment Programme. 
The National Institute of Clinical Excellence (NICE) is also in the process of working out an 
ICP for urinary incontinence and another has been proposed by the International Continence 
Society (ICS) in the 3
rd
 Consultation on Incontinence. 
 
The various pathways exhibit a common thread with the patients broadly undergoing five 
types of assessment; 1) clinical history 2) validated scales 3) physical examination 4) simple 
investigations 5) advanced investigations. 
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At least 5 publications have reported the benefit of the nurse led services (79-83). Most do 
not describe a comparator. Where controls were reported, they were non-specialist clinicians 
in primary or secondary care. The efficacy of specialist medical incontinence expertise in 
early management has not been disproved. 
 
A meta-analysis comparing nurse practitioner with doctors in providing care at first contact 
for minor illnesses reported more patient satisfaction with a nurse practitioner and no 
differences in outcome (84). “Patient satisfaction” is not necessarily a reliable assessment of 
the quality of care provided.  Horrocks et al. also reported that nurses had longer 
consultations and arranged more investigations than doctors. No differences were found in 
prescriptions, return consultations, or referrals. The longer consultation time by nurse 
practitioners has also been shown in other studies (85-87). The length of consultation (88;89) 
has been shown to be a good predictor of patient satisfaction. Increased consultation times are 
not assuredly beneficial; they increase costs and waiting times 
 
Staffing accounts for
 
70 % of NHS spending, so altering skill and grade mix is attractive. 
Some
 
fear the erosion of standards (90;91) and ask whether we really understand the 
properties of knowledge, skill and experience. (92).  
 
1.6.1   Are structure pathways suitable for diagnosis? 
 
There are very few trials on the diagnostic accuracy of assessment pathways. They rely on 
Boolean logic, which lies at the heart of the digital revolution and much database searching. 
By contrast, we teach diagnosis as an interchange between deduction, induction, abduction 
and Bayesian reasoning. The tools are knowledge, practise, experience and continuing 
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education. There is a contradiction at the heart of the ICP and problems with the veracity of 
the assumptions that underlie the pathways: For example, one of the earliest tests any ICP is 
some forms of urinalysis to exclude urinary tract infection. As will be discussed later, there 
are legitimate serious doubts about the validity of the tests being used to achieve this. If the 
tests are as insensitive as reported, the ICP falls at an early hurdle. Boolean decision nodes 
introduce additional serious errors: They stipulate a “yes” or “no” response without 
consideration of positive and negative predictive values, or the germane probabilities. There 
is no opportunity to consider the decision in the light of prior data or to revisit with posterior 
data. They therefore obviate skilled, professional diagnostic reasoning. 
 
A skilled, experienced clinician is capable of making accurate diagnostic and therapeutic 
decisions very rapidly, using a minimum dataset, collected through selective assessment. This 
does not employ the regimented steps in the standard ICP, actions being selective according 
to the symptom complex.  This is less time consuming and less expensive. There are good 
data supporting the cost-effectiveness of this approach (93). One of the key factors in the 
economic success of Kaiser Permanente is the deployment of their skilled workforce at the 
front (94). 
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1.7   Conservative treatments first?  
The pathways appear to rest on assumptions that have not been proven. Most propose a 
pyramidal structure that is contingent on the majority of persons with urinary incontinence 
being remedied by simple not medical-interventions. There are no data that validate this 
belief one-way or the other. All ICP’s recommend the use of “conservative” measures 
management, prior to investigative assessment. The evidence of the efficacy of conservative 
measures is sparse and contradictory. 
 
Below are reproduced the conclusions of the Cochrane reviews on conservative treatments 
for urinary incontinence in adults. The best claims are “weak evidence” or “suggestive 
evidence”. This means that there are no RCT data on the efficacy of these methods. Despite 
this, there remains a widespread belief that patients are better off if managed with 
conservative methods first. It is reasonable to ask “Where is the evidence for this dogma?”  
 
Bladder training for urinary incontinence in adults (Cochrane Review) (95) 
Definitive research has yet to be conducted: more research is required. 
 
Complementary and miscellaneous interventions for nocturnal enuresis in children 
(Cochrane Review) (96) 
There was weak evidence to support the use of hypnosis, psychotherapy, acupuncture and 
chiropractic but it was provided in each case by single small trials, some of dubious 
methodological rigour. Robust randomised trials are required with efficacy, cost-
effectiveness and adverse effects carefully monitored. 
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Habit retraining for the management of urinary incontinence in adults (Cochrane 
Review) (97) 
Data on habit retraining are few and of insufficient quality to provide a firm basis for practice. 
 
Mechanical devices for urinary incontinence in women (Cochrane Review) (98)  
Currently there is little evidence from controlled trials on which to judge whether their use is 
better than no treatment and a large well-conducted trial is required for clarification 
 
Pelvic floor muscle training versus no treatment, or inactive control treatments, for 
urinary incontinence in women (Cochrane Review) (99)  
Overall, the review provides some support for the widespread recommendation t PFMT be 
included in first-line conservative management programmes for women with stress, urge, or 
mixed, urinary incontinence. 
 
Physical therapies for prevention of urinary and faecal incontinence in adults 
(Cochrane Review) (100)  
There is insufficient evidence to determine whether physical therapies can prevent 
incontinence in childbearing women, or men following prostate surgery. Further, better 
quality research is needed. 
 
Prompted voiding for the management of urinary incontinence in adults (Cochrane 
Review) (101)  
There was insufficient evidence to reach firm conclusions for practice. There was suggestive, 
although inconclusive, evidence of short-term benefit from prompted voiding and from 
adding the muscle relaxant, Oxybutynin to prompted voiding. 
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Prevention and treatment of urinary incontinence after stroke in adults (Cochrane 
Review) (102) 
There was suggestive evidence that specialist professional input through structured 
assessment and management of care and specialist continence nursing may reduce urinary 
incontinence after stroke. Data from trials of other physical, behavioral, complementary and 
anticholinergic drug interventions are insufficient to guide continence care of adults after 
stroke. 
 
Timed voiding for the management of urinary incontinence in adults (Cochrane 
Review) (103) 
The data were too few and of insufficient quality to provide empirical support for or against 
the intervention of timed voiding. 
 
Weighted vaginal cones for female stress urinary incontinence (Cochrane Review) (104) 
This review provides some evidence that weighted vaginal cones are better than no active 
treatment in women with stress urinary incontinence and may be of similar effectiveness to 
PFMT and electrostimulation. This conclusion must remain tentative until further larger high 
quality studies are carried out using comparable and relevant outcome measures. 
 
 
 
 
 
 
 44 
1.8   Drug therapy 
Medications used to treat urge incontinence and OAB symptoms are aimed at inhibiting the 
involuntary contraction of the bladder and improving bladder function. There are several 
types of medications that may be used alone or in combination: 
 Anticholinergic agents (oxybutynin, tolterodine, solifenacin, trospium, darifenacin, 
propiverine, fesoterodine)  
 Tricyclic antidepressants (imipramine, amitriptyline)    
The anticholinergic medications work by blocking the M3 and M2 receptors on the detrusor 
neuromuscular junction. All the members of these groups have additional properties that 
include calcium channel blocking activity and local anesthetic properties. Whether these extra 
effects bear any relationship to the efficacy of the drugs in clinical practice is not known. The 
anticholinergic groups have been a fertile source of “me-too” manufacture and there is a 
plethora of publications seeking to identify significant differences in efficacy or side effect 
profile. There is no convincing evidence of striking differences and efficacy does seem to be 
very similar in comparative clinical trials that have taken place. 
 
Atropine-resistant, nerve induced detrusor contractions have long been recognised and efforts 
are being made to find alternatives to the antimuscarinics. Attention focused on β3-
sympathomimetic agents and P2X purinergic receptor antagonists. Botulinum toxin, superior 
to antimuscarinic agents, inhibits co-transmission of acetylcholine and ATP. Noradrenaline 
acting at β3 sites inhibits detrusor contractions. Serotonin is also a known inhibitor of bladder 
contractions (189). It should be possible to augment the effect of an antimuscarinic by using 
another drug that works synergistically at these alterantive targets, but will be some years 
before these molecules come out of development. 
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Imipramine hydrochloride has been used in the in the treatment of childhood enuresis for a 
long time. Over 20 years ago it was recommended as a treatment for the overactive bladder in 
adults, but efficacy was limited and it was superseded by the advent of oxybutynin and others 
of this class (105). 
 
Imipramine inhibits reuptake of noradenaline and serotonin equally. Changes in postsynaptic 
beta-adrenergic receptor sensitivity and increased responsiveness of the adrenergic and 
serotonergic systems contribute to the mechanism of action. The drug partially blocks ionic 
currents mediated through P2X receptor channels (105). 
 
56 randomised trials of tricyclic drugs for nocturnal enuresis, involving 3624 children have 
been published. Cochrane report the quality of many of these trials as poor. Treatment with 
most tricyclic drugs (such as imipramine, amitriptyline, viloxazine, nortriptyline, 
clomipramine and desipramine) was associated with a reduction of about one wet night per 
week. Only 1 study of Imipramine in adults has been published, it is was conducted in the 
elderly but was underpowered (106). 
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1.9   Surgery 
The goal of any surgery to treat  bladder  overactivity is aimed at increasing the storage 
ability of the bladder while decreasing the pressure within the bladder. Surgery is reserved for 
patients who are severely debilitated by their incontinenc and who have an overactive bladder 
symptoms and poor ability to store urine. 
 
For many years the augmentation cystoplasty was the most frequently performed surgical 
procedure for severe urge incontinence. In this reconstructive surgery a segment of the bowel 
is, de-tubed and then sewn into the bladder which has been opened like a clam. The bowel 
patch so placed separates the two halves of the bladder. 
 
Possible complications include those of any major abdominal surgery, including bowel 
obstruction, blood clots, infection, and pneumonia. There is a risk of developing urinary 
fistulae, urinary tract infection, and   urinary retention. Augmentation cystoplasty is also 
increased risk of developing carcinoma in the patch. It can also lead to metabolic 
disturbances and stone formation (190). 
 
Nowadays it is more usual for the intervention to be a botulinum toxin injection. There are 7 
immunologically distinct antigenic subtypes of botulinum toxin, of which type A is the most 
widely used. Botulinum toxin A (Botox) is a purified neurotoxin complex, which blocks the 
release of acetylcholine and other transmitters from presynaptic nerve endings. Thus nerve-
mediated contractions of the detrusor become inhibited. The effect is not permanent and tends 
to dissipate over the ensuing 6 months leading to a requirement for repeat injections. Botox 
cannot cross the blood–brain barrier and hence has no CNS side effects. A Cochrane review 
of Botulinum toxin injections for adults with overactive bladder syndrome (107) published in 
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2007 concluded “Intravesical botulinum toxin shows promise as a therapy for overactive 
bladder symptoms, but as yet too little controlled trial data exist on benefits and safety 
compared with other interventions, or with placebo.” Since then several RCT’s have been 
published with good results (108-112).  
 
The side effects of this treatment include dry mouth, dry eyes, gastro-oesophageal reflux, 
constipation, and not often urinary retention. Botox can lead to transient hypoasthenia that 
resolves by itself. 
 
The role of has been included under the Surgery section as it is classified as a surgical 
procedure though mostly it can be undertaken as an outpatient procedure under local 
anaesthetic.
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CHAPTER 2 
URINE INFECTION 
 
2.1   Acute urine Infection 
The American Foundation for Urological Diseases reports that acute bacterial cystitis affects 
8 – 10 million Americans a year and most of these patients are women. The National Institute 
of Diabetes and Digestive and Kidney Diseases notes that acute cystitis prompts about 9.6 
million doctor visits annually; $4.5 billion is spent on 11 million antibiotic prescriptions. 
Occurring in otherwise healthy young women with no congenital, neurological or structural 
abnormalities, acute, symptomatic, uncomplicated urinary tract infection (UTI) or acute 
female cystitis (AFC) is the most common infection (113;114) next to the common cold.  
25 to 40 % of females will experience an acute UTI in their lives, and up to 6 % of women 
will have one or more UTI in a given year (115;116). After an initial infection,
 
most women 
have sporadic recurrences, and a quarter to half
   
have another infection within one year. 3 to 
5 % have
 
recurrent urinary tract infections - that is, symptomatic
 
infections that follow the 
clinical resolution of a previous
 
episode, generally (but not necessarily) after treatment (117). 
 
The probability of cystitis in a woman with dysuria, urinary
 
frequency, or gross haematuria is 
about 50 %  in primary
 
care settings (118). Symptoms suggesting vaginitis or cervicitis,
 
such 
as vaginal irritation or discharge, reduce the likelihood
 
of a diagnosis of cystitis by about 
20 %. Specific combinations
 
of symptoms (e.g., dysuria and frequency without vaginal 
discharge
 
or irritation) raise the probability of cystitis to more than
 
90 %. When a woman 
who has previously had cystitis has
 
symptoms suggesting a recurrence, there is an 84 to 92 %
 
chance that an infection is present (119;120).  
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2.2   Chronic / Recurrent Urine Infection 
Chronic urinary tract infection is a disorder involving repeated or prolonged bacterial 
infection of the bladder or lower urinary tract (urethra). The term “Cystitis” refers to the 
bladder which is most commonly affected. This occurs when the normally sterile lower 
urinary tract is infected by bacteria and an inflammatory response is induced. The symptoms 
of acute cystitis usually disappear within 24 - 48 hours after treatment begins. Recurrent 
cystitis may be either a re-infection (after successful eradication of infection) or a relapse 
after inadequate treatment. Chronic or recurrent urinary tract infection includes repeated 
episodes of cystitis, there being more than 2 in 6 months, or urinary tract infection that does 
not respond to antibiotic treatment or lasts longer than 14 days (121). In young girls, 
recurrent urinary tract infections may be an indication of a urinary tract abnormality, such as 
vesico-ureteral reflux, and hence imaging assessments are recommended. Urinary tract 
infections in boys are extremely uncommon in the absence of urinary tract abnormalities so a 
single episode of cystitis should result in imaging studies. 
 
Amongst the elderly, cystitis acute and chronic is much more common due to incomplete 
emptying of the bladder, prostatism, immunoparesis, diabetes, vascular disease, low fluid 
intake, faecal incontinence, decreased mobility, and the use of indwelling catheters are the 
most commonly proposed aetiological factors although the truth is yet to be verified with 
rigor. 
 
In truth, this entity is no more than a clinical definition based on arbitrary time frames. The 
literature is signally sparse in explaining the pathophysiology. Hultgren et al. have discovered 
that in their murine model, populations of E.Coli can persist in the bladder for months on end, 
during which time they exist in a quiescent reservoir (122). 
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2.3   Aetiology of UTI 
The microbial aetiology of urinary infections has been regarded as well established and 
reasonably consistent. Escherichia coli remains the predominant uropathogen (80 %) isolated 
in acute community-acquired uncomplicated infections, followed by Staphylococcus 
saprophyticus (10 to 15 %). Klebsiella, Enterobacter, Proteus species, and Enterococci 
infrequently cause uncomplicated cystitis and pyelonephritis. Fungal pathogens like Candida 
albicans or other Candida species, account for up to 10 % of positive urine cultures in tertiary 
care (123), but most of these are in complicated UTI’s. The aetiology of UTI is also affected 
by underlying host factors that complicate UTI, such as age, diabetes, spinal cord injury, and 
catheterization. It has been found that the most common organism grown deliberately in the 
laboratory is the E. coli (124;125) (126). The most common organisms isolated in children 
with uncomplicated UTI is E.coli but also Enterobacteriaceae group (127).  
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2.4   Pathogenesis of E. Coli UTI    
A critical initial step in the pathogenesis of both acute and recurrent UTI involves 
colonization of the urinary tract or vaginal introitus with E. coli. Uropathogenic E. coli strains 
generally possess filamentous surface adhesive organelles called fimbriae or pili. In case of 
type 1 fimbriae, the adhesin molecule Fim H, which is located at the tip of the type 1 pilus, 
directly interacts with host receptors and facilitates bacterial attachment on the luminal 
surface of the bladder epithelium. This may also mediate the internalization of bacteria into 
epithelial cells, where E. coli can replicate and escape host defense mechanisms. Research 
has shown that women with Recurrent UTI have 3-fold more E. coli adhering to vaginal, 
buccal, and voided urothelial cells than women without recurrent infection. Further, women 
with Recurrent UTI’s also have longer durations of vaginal colonization with uropathogenic 
E. coli (128), even during asymptomatic periods (129). Each E. coli clone has distinct 
characteristics, including O and K serotype, similar outer membrane protein patterns, and 
hemolysins. Some O and K serotypes of E. coli are more common uropathogens than others. 
Nevertheless, P fimbriation appears to be a virulence factor. Further, there appears to be a 
correlation between colonization of the gastrointestinal tract with P-fimbriated E. coli and 
acute pyelonephritis (130). In some patients with diabetes, Tamm-Horsfall protein is 
markedly reduced, allowing adherence and cell entry of type 1 fimbriated E. coli (131). 
Whereas P fimbriation and hemolysin production have been identified as important virulence 
factors among patients with diabetes (132),  there is as yet, no evidence identifying 
differences in bacterial virulence factors for E. coli among patients with or without diabetes. 
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2.5   Pathogenesis of Non – E. Coli UTI 
In contrast to the pathogenesis of E. coli UTI, S saprophyticus and enterobacterial species 
adhere to urothelial cells through different adhesive mechanisms. After attachment, Proteus 
spp., K pneumoniae, and S saprophyticus each produce urease, which catalyzes the 
hydrolysis of urea in urine and causes the release of ammonia and CO2. As a result, the 
urinary pH is elevated causing the alkalinisation of urine that leads to the formation of 
bladder and kidney stones. 
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2.6   Interstitial Cystitis/ Painful Bladder syndrome 
Skene et al. first muted the term interstitial cystitis in 1887 (133), but widely acceptable 
diagnostic criteria for interstitial cystitis was developed in 1987, at a meeting convened by 
the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)  in the USA 
(134). The mucosal ulcers were a preliminary criterion, which was first identified by Hunner 
et al. in 1914 (135). Pain on bladder filling that was relieved by emptying as well as 
suprapubic, pelvic, urethral, vaginal or perineal pain and/or glomerulations (urothelial 
haemorrhages elicited by bladder hydrodistention) were deemed positive factors for 
Interstitial Cystitis, of which 2 were required for diagnosis. 
 
Pain was a prominent part of the case definition discussion at the 1987 NIDDK meeting. 
Gillenwater et al. introduced Interstitial Cystitis by referring to “painful bladder disease.” 
Holm-Bentzen et al. presented extensive data on “the painful bladder syndrome.”(134). Held 
et al. surveyed 127 board certified urologists about their experiences with patients with 
interstitial cystitis and pain was ranked as the single most common criterion for diagnosing, 
while “pain on filling and relieved by emptying” was ranked 4th and non-pain symptoms were 
ranked lower, including urgency as 7
th
, nocturia as 17
th
 and waking frequency as 19
th
  (136). 
Pain exacerbation can be due to stress, sexual intercourse, tight clothing, as well as due to 
consumption of acidic beverages, coffee and spicy foods.  
 
Use of the phrase painful bladder syndrome (PBS) goes back at least to 1951 (137). In 1987 
in a clinical trial of “interstitial cystitis and painful bladder disease” Holm-Bentzen et al. 
described PBS in terms similar to those for IC (138). Since 1976, the ICS has standardized 
the terminology of lower urinary tract diseases and in 2002 it reported PBS for the first time. 
“Painful bladder syndrome is the complaint of suprapubic pain related to bladder filling, 
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accompanied by other symptoms such as daytime and night time frequency, in the absence of 
proven urinary infections or other obvious pathology.” (138;139). 
 
The footnote on a report also recommended that interstitial should be defined as a condition 
that is symptomatically the same as PBS in terms of pain and other symptoms, such as 
frequency, but must be confirmed clinically. “The ICS believes this to be a preferable term to 
‘interstitial cystitis.’ Interstitial cystitis is a specific diagnosis and requires confirmation by 
typical cystoscopic and histological features.” (138;139) 
 
These features typically include ulcers or glomerulations observed on the bladder wall. Other 
committees recently came to similar conclusions about IC and PBS, and several suggested 
that the names should be combined into one term (4;140) (141)  
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2.7   Excluding urinary infection  
Unfortunately, in diagnosing OAB the exclusion of UTI poses a problem of great significance. 
Standard laboratory methods operate a diagnostic threshold of ≥105 colony forming units 
(cfu) ml
-1
. But Stamm et al. (142;143) found ≥102 cfu ml-1 was appropriate for persons with 
acute frequency/dysuria and that ≥105 cfu ml-1 missed 50 % of infections. The dipstick 
leukocyte esterase and nitrite tests have been calibrated to ≥105 cfu ml-1. The OAB literature, 
reassured by these tests, may not have addressed infection adequately.  
 
At the moment the best surrogate marker of urinary infection, superior to routine culture and 
dipstick analysis, is the detection of ≥10 white blood cells (wbc) per µl-1 of fresh, unspun 
urine, examined in a haemocytometer (144). This has been well validated. 
 
2.7.1   The history of pyuria as a surrogate marker of infection 
Since 1957 the diagnosis of urinary tract infection (UTI) from culture of a mid-stream urinary 
specimen (MSU) has rested on criteria described by Kass et al. (1957) in his classic paper 
(125).  He reported that the MSU’s of 25 patients with chills fever, flank pain and dysuria had 
grown more than 10
6
 bacteria colony forming units per ml (cfu ml
-1
). After studying the MSU 
in asymptomatic people, he concluded that “For survey purposes a count of 105 cfu ml-1 of a 
known urinary pathogen should be designated, arbitrarily as the dividing line between true 
bacilluria and contamination”. Kass never claimed to define a threshold for use with cystitis 
symptoms. However 10
5
 cfu ml
-1
 has been widely adopted in clinical practise. 
 
In 1982 Stamm et al. (143) published work conducted on acutely dysuric women. He 
discovered that in the presence of the classical symptoms of acute cystitis, a culture result of 
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10
2
 cfu ml
-1
 was a more appropriate threshold for diagnosis. There are no data on a threshold 
applicable to patients with other lower urinary tract symptoms. 
 
The MSU nowadays is usually, processed using semi-automated methods. These are 
generally set to a threshold of 10
4
 cfu ml
-1
 which is higher than Stamm’s threshold of 102 cfu 
ml
-1
 for cystitis (113). Hooton & Stamm et al. have reported that laboratory MSU cultures 
miss over 50 % of genuine infections (145). 
 
An alternative method of diagnosing urine infection is the identification of significant pyuria. 
The determination of the excretion rate of white blood cells in urine was first described by 
Hottinger et al. in 1893. Nevertheless, the technique used is usually attributed to Addis et al., 
who published his method in 1925, referred to as the “Addis count” (146). The method is 
laborious and impractical.  
 
Hamburger et al. in 1950 (147), and Houghton and Pears et al. in 1957 (148) described 
modifications of the Addis count which made it simpler but reliable, although a catheter was 
used to collect the urine. The leucocytes were enumerated by examining the urinary sediment 
in a haemocytometer.  
 
Hamburger, Houghton and Pears et al. obtained the sediment by centrifugation of 10 ml of 
urine at 1500 rmp (radius 12 cm) for three minutes. 9 ml of supernatant was removed and the 
1 ml of sediment remixed with a Pasteur pipette before spreading on the haemocytometer 
chamber to count the leucocytes. Having used this technique in volunteers, they concluded 
that the normal rate of leucocyte excretion varied between 18,000 and 196,000 per hour.  
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The upper limit of the normal leucocyte excretion rate per hour was established as 200,00 
wbc h
-1
 to 400,000 wbc h
-1
 by Houghton and Pears at al. in 1957 (148-151) all of whom 
demonstrated excretion rates of >400,000 wbc h
-1
 in patients with proven, symptomatic 
urinary infection.  Little et al. (1962) successfully evaluated the mid-stream urine (MSU) as 
an alternative to catheter collection. In his method, there was no interruption of the urinary 
stream during collection (151). 
 
In 1968, Mabeck et al. attempted to simplify evaluation by counting the white cells per high 
powered field (x40 objective x10 optical = x400pf) using the unresuspended, stained, 
sediment. All patients showing 3 or more wbc per high powered field (x, hpf) excreted more 
than 400,000 wbc h
-1
, but fewer than 3 wbc phpf did not exclude excretion rates of  ≥400,000 
wbc h
-1
. The spun sediment underestimated the leucocyte excretion rate,  presumably because 
of cell destruction during centrifuging (152). 
 
Mond et al. (1965) examined unspun fresh urine and counted the white cells using a 
haemocytometer, finding that ≥10 wbc mm-3 were noted in all patients with symptomatic 
acute cystitis and bacteriuria (10
5
 cfu ml
-1
) (153). In 1968 Gadeholt et al. compared the 
examination of spun and unspun specimens and showed that the calculated excretion rates on 
uncentrifuged specimens showed higher values (154;155). This confirmed earlier suspicions 
that centrifugation caused loss of cells. Gadeholt et al. (1968) showed that all patients with 
≥10 wbc mm-3, of unspun urine, excreted >400,000 wbc h-1; This was confirmed by Mabeck 
in 1969 (156) and by Baerheim et al. (1989), all of whom identified the problem with 
centrifugation. Thus the finding of ≥10 wbc mm-3 (µl) , of unstained, unspun urine examined 
on a haemocytometer, became established as the most effective method for diagnosing 
urinary infection (157). 
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Latham et al. (1984) publishing with Stamm reported that the detection of pyuria ≥10 wbc 
mm
-3
 was the most accurate and efficient method of identifying urinary tract infections in 
ambulatory women with symptoms of acute cystitis (158). 
  
Whilst Stamm et al. has achieved much in clarifying the diagnostic criteria useful with 
classical symptoms, there remains a problem with non-dysuric lower urinary tract symptoms.  
It is no longer reasonable to rely on the reassurances of bacteriuria of <10
5
 cfu ml
-1
. 
 
A convenient alternative to MSU analysis is the dipstick test for leucocyte esterase test. 
Using a diagnostic threshold of 10
5
 cfu ml
-1
, this has a reported sensitivity of 75 to 90 % in 
detecting significant pyuria. There are no data related to a culture threshold of 10
2
 cfu ml
-1
 in 
the presence of cystitis symptoms (159-161). 
 
There have been 2 meta-analyses of urinary dipsticks, used to assess acute frequency/dysuria, 
in adults (162;163) and 1 in children (164). Hurlburt and Littenberg et al. concluded that 
dipsticks cannot exclude infection reliably in most clinical settings. Deville et al. (162) 
reported leucocyte esterase sensitivity of 0.76 (95 % CI 0.6 to 0.98) and specificity 0.46 
(95 % CI 0.32 to 0.68) for the diagnosis of urinary infection and a nitrite sensitivity of 0.49 
(95 % CI 0.38. to 0.62) and specificity of 0.85 (95 % CI 0.73 to 1.0) in primary care.  
 
In relation to OAB in contrast to acute cystitis or acute frequency/dysuria there are no 
published data on an appropriate threshold for the diagnosis of pyuria. Therefore, for the 
purposes of this thesis, it was thought wise to err on the conservative side and describe pyuria 
as  ≥1 wbc µl-1.  
 
 60 
It will be prudent to discuss the role of other inflammatory markers in the diagnosis of urine 
infection, although it is not a part of this thesis. The role of Urothelium and the inflammatory 
markers have been discussed briefly in the chapter of pathophysiology, earlier.  It has been 
described about elevated Interleukins in upper urinary tract infections in children (191). 
Similarly elevation of serum C-reactive protein and urinary Nerve Growth factor has been 
shown to be elevated in states of chronic inflammation of the urinary bladder (192). 
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CHAPTER 3 
 
SQUAMOUS METAPLASIA 
 
It would be inappropriate to discuss any chronic inflammatory condition affecting the bladder 
without introducing the matter of metaplasia. 
 
Metaplasia is the reversible replacement of one type of adult tissue by another type. 
 
Squamous metaplasia refers to benign changes in the epithelial lining of certain organs within 
the body. These cells assume a more squamous morphology. Common sites for squamous 
metaplasia include the bladder and cervix. Smokers often exhibit squamous metaplasia in the 
linings of their airways. These changes don’t signify a specific disease, but represent the 
body’s response to stress or irritation. 
 
Replacement of urothelium by stratified squamous epithelium could entail non-keratinised (v) 
and keratinized subtypes of squamous cells. 
 
The non-keratinized subtype is found commonly in the trigone area and the keratinized 
subtype in the rest of the bladder. 
 
The presence of non-keratinised squamous metaplasia in the bladder is also called 
pseudomembranous trigonitis, trigonal cystitis, urethra-trigonitis, and vaginal metaplasia of 
trigone. It should be no surprise that this plethora results in much confusion. 
 
 
 63 
The keratinized squamous metaplasia in the bladder is called as leukoplakia and is closely 
associated with Vit. A deficiency (165). 
 
Pseudomembranous trigonitis commonly affects the female trigone and is defined as partial 
or complete replacement of urothelium by mature squamous epithelium and it is diagnosed 
macroscopically by the presence of white patches or plaques visible on the trigone 
endoscopically (166). 
 
The condition was first described as “Cystitis Trigoni” by Heymann et al. in 1905. 
 
We do not know whether squamous metaplasia should be considered a normal variant of 
trigonal urothelium in women. Wiener et al.  (167) detected non keratinised  squamous 
metaplasia in 40 % and 5 % of female and male trigone’s, respectively in “normal bladders” 
at autopsy. They are far from explicit in how they defined a normal bladder for their purposes. 
 
The ratio of mitotic cells to resting cells, the mitotic index, of pseudomembranous trigonitis is 
0.17 %, which is significantly higher than normal (≈ 0%) (168). 
 
Leukoplakia undergoes three successive stages – squamous cell modulation, squamous cell 
metaplasia and squamous cell metaplasia with keratinisation. It has been shown to have 
precancerous potential (168). 
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3.1              Histopathology 
 
Normal trigonal urothelium consists of three cell layers (basal, intermediate and superficial) 
whereas pseudomembranous trigonitis constitutes many layers of stratified squamous 
epithelium. 
 
The urothelium forms effective permeability barrier and can withstand repeated stretch and 
contractions (169). To perform these functions the apical surface of urothelium becomes 
highly specialised as it is covered almost completely for 16 nm depth by uroplakin particles 
that are packed hexagonally (170). 
 
In squamous metaplasia, the basal cells contain prominent nuclei with condensed chromatin, 
nucleoli and nuclear bodies. The basal region is two to three cells in thickness and consists of 
the smallest cells. The shape of cells in this basal region is cuboidal or columnar. The 
cytoplasm of these cells is rich in mitochondria. The profiles of the urothelial cells become 
progressively elongated, nuclei increasingly smaller and the content of cell organelles 
gradually reduced as the luminal surface is approached. 
 
The squamous surface cells, linked by desmosomes, retain many longitudinally arranged fine 
filaments, together with an occasional degenerate nucleus and a pale staining cytoplasm.  
 
When the glycogen is abundant and there is vacuolisation, the metaplastic urothelium may 
resemble the vagina. 
 
Whilst this non-keratinized squamous metaplasia is considered to be benign, there is a report 
of atypical hyperplasia found in two cases of non-keratinized metaplasia (171). 
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3.2   Inflammatory Features 
The incidence of inflammatory features has been assessed as about 30 % (171).  These 
manifest lymphoid follicles and/or plasma cells within the tunica propria and prominent 
venous channels forming a plexus about the urethral orifice. There was also oedema and 
vascular dilatation underlying areas of non-keratinized metaplasia (166). 
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3.  Clinical correlations 
Pseudomembranous trigonitis may be related to frequency and urgency symptoms (172). 
Brawn et al. (1984) proposed that squamous metaplasia may be less efficient in maintaining 
the barrier between blood and the urine. In normally differentiated three-layered trigonal 
urothelium, the retention in the upper strata of some internal cytoskeleton, external 
membranous and desmosomal connections might be functionally important as blood urine 
barriers (168). 
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3.4   Concomitant  pathology 
Non-keratinised squamous metaplasia of the trigone was considered an adaptive response to 
inflammation of the bladder in many earlier reports (173).
 
Other reports suggest that Non-
keratinised squamous metaplasia may predispose to the development of chronic cystitis. 
 
Davies and Hunt et al. demonstrated bacilli adherent to the surface epithelium of the bladder 
trigone in a woman with recurrent urinary tract infections. Others have concluded that there is 
a variation in the histological appearance of vaginal metaplasia with phases of menstrual 
cycle under the hormonal influence of oestrogen (174-176). 
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CHAPTER 4  
 
4.1                Experimental  plan which led to this study 
 
Malone-Lee et al .(177)  studied 785 patients ( mean age ± SD = 54 ± 19 years:  717 females 
and 68 males) with overactive bladder symptoms over a four year period (April 2003 to 
March 2007; (1). Using the more stringent criteria to examine fresh, unspun urine samples by 
light microscopy with a haemocytometer it was found that 58% (n=452) of the specimens 
demonstrated significant pyuria ≥10 wbc μl-1. Of these, only 12 % (n=53) showed a 
significant pure growth on culture and 9 % (n=40) showed a mixed growth. Thus the MSU 
culture was sterile in 79 % (n= 359) of urine samples showing pyuria ≥10 wbc μl-1. 68 % of 
the specimens (n=535) tested “Trace positive” or greater to dipstick leucocyte esterase and of 
these 83 % (n=446) were sterile and 69 % (n=371) showed pyuria ≥10 wbc μl-1 on 
microscopy.  
 
Of the 452 specimens, which showed pyuria ≥10 wbc μl-1, only 8 % (n=36) were dipstick 
nitrite positive. Of the 55 specimens, which showed a pure bacteriuria (≥ 104 cfu ml-1), only 
16 % (n=9) were dipstick nitrite positive.  
 
Between those with pyuria ≥10 wbc μl-1 and those without there was a significant difference 
in average 24-hour urinary frequency and incontinence episodes (Pyuria ≥10 wbc μl-1 versus 
no pyuria (zero wbc μl-1): Urinary frequency 95 % CI -0.96, -0.15, F=6.5 p=0.011; 
Incontinence episodes 95 % CI -0.28, -0.07, F=25, p<0.001).  
 
During the observation period 74 % (n=579) of the study population demonstrated significant 
pyuria ≥10 wbc μl-1 at some time, with this being slightly more common in older persons; 
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70 % of patients aged ≥50 years showed pyuria ≥10 wbc μl-1 compared to 63 % under 50 
years.  
 
Despite sterile MSU cultures, the pyuric patients were treated with antibiotics for varying 
lengths of time until the pyuria ≥10 wbc μl-1 cleared (Median days of antibiotic treatment: 
154 Interquartile range = 164 days). Patients being treated with antimuscarinics had worse 
symptoms if they had pyuria ≥10 wbc μl-1 than if they did not (95% CI Diff frequency -1.0, -
0.05, F= 6.6 p=0.01 and 95 % CI Diff incontinence -0.3, -0.03, F=17, p<0.001). 
 
When pyuric only 8 % (n=46) of patients described dysuria. More common dysaesthesic 
symptoms were; loin (30 %) and suprapubic discomfort (29 %) and vague abdominal 
discomfort (23 %). The symptom complex had much in common with those described in 
Interstitial Cystitis. 
 
Thus is preliminary work demonstrated a urinary inflammatory reaction in more than 50 % of 
patients with OAB symptoms, associated with worse symptoms, particularly incontinence, 
despite antimuscarinics treatment. 
 
The slow response to antibiotics compliments an important experiment by Anderson et al. 
(2004) (122;179). Using a mouse model of urinary tract infection, they demonstrated the 
ability of E. coli to colonise the superficial umbrella cells of the bladder with intracellular 
biofilms, exhibiting striking antibiotic and immune resistance. Electron microscopic studies 
showed these biofilms forming pod-like protrusions on the cell wall with the bacterial 
encased polysaccharide  rich matrix surrounded by a protective shell of uroplakin. This could 
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explain the Malone-Lee et al. (177) , experience that  sustained antibiotic treatment was 
necessary to clear infection effectively. 
 
The sensory symptoms elicited from the patients fit well with current discoveries about ATP. 
Activation of P2X 2/3 and P2X7 receptors by ATP, released in response to inflammation, has 
been implicated in atypical dysaesthesia. The symptoms experienced by the patients in the  
Malone-Lee et al.(177) series compliment these discoveries. 
 
Sterile pyuria accords with Stamm’s discoveries. An apparent slow response to antibiotics 
chimes with contemporary mouse experiments (122;179).  The phenomenon might explain 
antimuscarinics resistance, fluctuant symptoms and recovery on placebo. Although  Malone-
Lee et al. (177) obtained a large sample, with blinding between microbiology and clinician, 
these were only observational data requiring validation by rigorous methods. 
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4.      The Objectives 
It has been shown by these means that pyuria would seem to be under-diagnosed in patients 
with OAB symptoms because of the methods that have been used in its assessment. The data 
indicate that it is an extremely common complication. Whilst the earlier experiments 
identified pyuria as ≥10 wbc μl-1, this threshold was worked out in the context of acute 
urinary tract infection symptoms and may not be appropriate to OAB group so from this point 
in time, pyuria is going to be taken as ≥1 wbc μl-1. 
 
There are a number of questions that need to be resolved through a sequence of clinical 
experiments to find out the significance of pyuria – 
 
1) What is the morphological profile of the inflammatory reaction? 
 
2) Could the detection of a urinary inflammatory response be enhanced by analysis of 
urinary spun sediments prepared using methods developed for cytology? 
 
3) Is there confirmatory histological evidence of urothelial inflammation associated with 
culture-negative pyuria or OAB symptoms without pyuria? 
 
4) Is there evidence of undue urothelial stress; manifest by increased urothelial cell 
denudation, hyperplasia and metaplasia, in patients experiencing persistent pyuria ≥1 
wbc µl
-1
 and overactive bladder symptoms? 
 
5) What additional information does electron microscopy throw onto the 
pathophysiology of the urothelium in OAB symptoms associated with pyuria? 
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4.3   Hypotheses tested 
Five hypotheses were formulated for testing. OAB symptoms with pyuria ≥10 wbc μl-1 are 
associated with the following pathophysiological phenomenon – 
 
(1) Urothelial inflammation results in a coherent chronic/acute inflammatory cell 
response.  
 
(2) A Shandon Cytospin™ preparation suitably stained will prove a more sensitive 
detector of urinary inflammatory activity in patients with OAB symptoms, than 
current routine clinical methods. 
 
(3) Urothelial inflammation, oedema and cell denudation should be detected by histology 
of H&E stained biopsies obtained from affected patients. 
 
(4) The patients should demonstrate increased urothelial cell denudation; hyperplasia and   
metaplasia detected by histology of H&E stained biopsies and urinary spun sediments. 
 
(5)  The patients should demonstrate e of morphological alterations in the  
urothelium detected by transmission electron microscopy 
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CHAPTER 5  
 
METHODS 
 
5.1   Sampling 
The study was submitted for approval to The East London Research Ethics Committee which 
reviewed proposal study and approved its enactment. 
 
The study was initiated to test the hypotheses related to urothelial inflammation associated 
with OAB symptoms that were articulated at the end of the last section. The experiments 
required recruitment and screening of the patients referred to the incontinence clinic at the 
Department of Medicine, Whittington Campus, UCL Medical School. Control patients were 
recruited from hospital staff and medical students for the provision of urine samples whereas 
control biopsy material was obtained from wholly asymptomatic patients attending a one-stop 
haematuria clinic at the same site.  
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5.2   Study Population 
 
5.2.1   Subject Inclusion Criteria 
1.  Adults aged ≥18 years 
2.  Males 
3.  Females  
4.       Symptoms of frequency ≥ 8 per day; urgency with or without urge 
 incontinence  i.e. OAB symptoms 
5.       Pyuria of  ≥1 wbc µl-1 (OAB Pyuria patients)  
6.        No Pyuria of zero wbc µl-1 (OAB Non-Pyuria patients) 
7. A group of asymptomatic normal volunteers matched for age and sex      
termed  "Normal controls" 
8. A group of asymptomatic patients undergoing routine flexible cystoscopy 
 because of an episode of microscopic haematuria, termed "Asymptomatic 
 control patients" 
9. Able to complete a validated symptom questionnaire 
 
5.2.2  Subject Exclusion Criteria 
1.  Adults aged <18 years 
2.  Inability to consent 
3.  Suffering from a significant concomitant urinary tract pathology likely to 
 cause urinary infection of the bladder in its own right; such conditions 
 would  include chronic obstruction, catheterisation, neurological disease, 
 prior  radiotherapy, anatomical defects or the presence of implanted devices 
4.  Pregnancy 
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5.  Bleeding disorders / on Anticoagulants 
6.       Diabetes 
7.       Urinary Tract Infection 
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5.3   Enrolment Procedures 
5.3.1   Screening 
 
Eligible patients were identified from Professor Malone-Lee’s incontinence clinic and the 
routine one stop haematuria clinic at the Whittington Hospital NHS Trust. The 
"Asymptomatic Normal controls" were identified via the recruitment of normal healthy 
volunteers from the staff at the same institution. 
 
5.3.2   First Contact 
Suitable patients were written to with a brief lay description of the study asking whether they 
would be willing to consider helping.  
 
5.3.3   Visit One - Initiation visit 
The patients were seen in the Incontinence clinic. Urine samples were collected on verbal 
consent as this formed a part of normal routine clinical practice. However, all patients had a 
written explanation of urine analysis that was planned. The patient’s symptoms were 
collected by use of a standardised validated questionnaire (67). The data were stored onto a 
bespoke clinical database and in a case record form (CRF). A unique ID number was then 
assigned from a chronological sequence. A catheter specimen of urine (CSU) and/or 
meticulous midstream urine specimen (MSU) only from male were collected. A CSU is the 
preferred sampling method in the normal clinical practice because of the superior quality of 
the specimen. The specimen was then processed as follows – 
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1. An urine aliquot was tested with dipsticks and the results recorded onto Artemis and 
the CRF. 
2. An urine aliquot was examined using a haemocytometer, the constituent cells counted, 
and the data recorded onto Artemis and the CRF. 
3. An urine aliquot was sent for routine microscopy, culture and sensitivity to the 
microbiology laboratory (threshold of 10
5 
cfu ml
-1
). 
4. An urine aliquot sample was centrifuged in a Shandon Cytospin™ to prepare a single 
cell layer preparation of the spun sediment. These were stained by Giemsa and Pap 
stain.  
 
All patients, not "Normal controls", were then asked about undergoing a cystoscopy and 
bladder biopsy using local anaesthetic and a flexible cystoscope, as a day case procedure. 
Those patients agreed to undergo this procedure were issued with an additional information 
sheet and another attendance was booked. The majority who agree to this were to undergo 
Botox injections and a biopsy at the time of this event was a much less inconvenient 
imposition. 
 
5.3.4   Visit Two – Pre-biopsy 
An informed consent form was signed. The usual urological preoperative assessment was 
accomplished and the attendance date for cystoscopy and biopsy was booked.  
 
5.3.5   Visit Three – Day care unit 
At the time of admission in the day-care unit the surgical staffs were warned of the need for a 
research-related tissue biopsy and the appropriate preparation was effected. The patient’s 
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willingness to provide a gift of a tissue biopsy was re-confirmed at the time of admission by 
the undertaking clinician (myself). 
 
The biopsy sample was collected according to the instructions, which were placed in the 
medical notes. The collection of the specimen and the reception by the researcher and the 
team was recorded in the hospital notes. The study patient completion page was finished and 
signed by the researcher/investigator and the fact recorded in the hospital notes. 
 
5.3.6   Visit Four – Follow up visit 
The patients were seen in the Incontinence clinic so as to follow their progress and to ensure 
that they had not encountered any adverse effects from the research biopsy. The patient’s 
symptom data was collected and recorded onto, a bespoke clinical research database called 
“Artemis” that is used for all of the clinical studies conducted in this centre.  
Their future care was arranged by supervision in the incontinence clinic. 
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5.4   Clinical  Evaluations 
 
5.4.1   Concomitant  Medications  
These were recorded in the Artemis database at the first visit. 
 
5.4.2   Concomitant  Treatment  
This was also recorded in the Artemis database at the first visit. 
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5.5   Diagnostic Category 
Categorisation of bladder function according to one of the following diagnostic categories 
utilising the patient’s clinical history and medical notes: 
1) OAB with zero pyuria 
2) OAB & pyuria ≥1 wbc μl-1 
3) Asymptomatic Normal controls 
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5.6   Laboratory  Evaluations 
 
5.6.1   Clinical Laboratory Evaluations 
 
1. Fresh urine light microscopy using a Haemocytometer 
2. Chemical urinalysis: dipstick urinalysis 
3. CSU / MSU to the microbiology laboratory for routine culture 
4. Shandon CytospinTM sediment preparations 
5. Giemsa and Pap staining of the prepared CytospinTM slides 
6. Bladder biopsy for histology after H&E staining 
7. Bladder biopsy for transmission electron microscopy  
 
5.6.2   Urological  Intervention 
1. Flexible cystoscopy and bladder biopsy 
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5.7   Procedures 
5.7.1   Collection of a Catheter specimen of Urine (CSU) 
The CSU was collected from the patients attending the incontinence clinic.  
 
Equipment 
Medicated swab (saturated with isopropyl alcohol 70 %) 
Sterile saline 
Universal specimen container 
Disposable gloves 
Single use catheters esp. Jacques 
 
Procedure 
After explaining the procedure to the patient, appropriate consent was obtained. The hands 
were washed using soap and water, dried thoroughly and the operator wore disposable gloves 
to minimise the risk of cross-infection. The perineum was cleaned with sterile normal saline 
solution and Jacques (“in and out”) size 12 Fr catheter (Mediquip, Devon, UK) was inserted 
in the urinary bladder under aseptic conditions using “No Touch technique”. The initial 5 ml 
was discarded and the rest of the urine was collected into a universal container. The urine 
specimen was divided into 3 different aliquots. (A) 1st aliquot was labelled and dispatched to 
the laboratory as soon as possible after sample was taken for routine culture. (B) The 2nd 
aliquot was used for dipstick testing and fresh urine microscopy, (C) The 3rd aliquot of urine 
was subjected to cytocentrifuge in a Shandon Cytospin™ to prepare two slides of single cell 
layer preparation for subsequent staining with Giemsa and Pap stain. 
 
The type of specimen taken was documented in the patient’s notes. 
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5.7.  Collection of a meticulous mid-stream specimen of Urine  
  (MSU) 
The MSU was collected from male patients attending the incontinence clinic or from the 
normal controls. 
 
Equipment 
Universal specimen container 
 
Procedure 
Verbal consent was obtained. The patients were told to provide meticulous clean catch mid 
stream uninterrupted urine. They were asked to initiate voiding into the toilet and after a 
pause pass the universal container into the stream to collect a specimen and then out of the 
stream so that voiding could be completed into the toilet.  The urine specimen was divided as 
described above (CSU section).  
 
The type of specimen taken was documented in the patient’s notes. 
 
5.7.3   Fresh urine Microscopy using Haemocytometer 
 
The fresh unspun specimen of urine collected was subjected to microscopy using 
haemocytometer to evaluate for pyuria ≥1 wbc μl-1. The Haemocytometer is a special 
microscope slide.  It is thicker than normal and has a “chamber”, which is 0.1 mm deep, cut 
into it.  The chamber has a grid etched onto it, which can be seen under the microscope.  The 
grid is made of squares, rather like graph paper.   Each tiny square is 0.05mm x 0.05mm.  The 
“medium” squares (4 x 4 tiny squares) are 0.2 mm x 0.2 mm and the “large” squares are 1 
mm x 1mm (The volume of 1 large square = 0.1 x 1 x 1 = 0.1 mm
3
 or 0.1 μl). 5 large squares 
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have a volume of 0.5 mm
3 or 0.5 μl. The pus cells/ white blood cells (wbc) were counted in 
the 5 large squares and then doubled up to give the count of pus cells per µl. If a cell 
overlapped a ruled line engraving, it was counted "in" if it overlapped the top or right ruling; 
ignored as "out", if it overlapped the bottom or left ruling. This was standard counting to 
avoid any discrepancy. The image of Haemocytometer grid is obtained from online resource 
www.ruf.rice.edu/.../cellcounting.html and www.jove.com/index/details.stp?ID=262        
 
Figure 1  -   A Haemocytometer grid   (HPA Culture collections, Salisbury, UK) 
 
 
5.7.4   Dipstick urine analysis 
The fresh urine collected was subjected to dipstick analysis. The urine was dipped by a 
Multistix
®
 8 SG and read by a Clinitek Status colorimeter (Bayer Healthcare, Newbury, UK). 
The nitrite test pad sensitivity of the dipstick was stated to be 13-22 µmol/L (0.06-0.1 mg/dl) 
nitrite ions. Therefore if the urine sample contained nitrite ion in the range specified, the pad 
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would turn pink indicating a positive result. The leukocyte test pad sensitivity of the dipstick 
ranges between trace to > 2000 mg/dl. 
 
5.7.5   Routine culture method 
A urine aliquot collected either by CSU or MSU was labeled appropriately and conveyed to 
the hospital laboratory. The specimen was treated fresh, or after overnight storage at 4
0 
C.     
1 μl of unspun urine was transferred by loop to a chromogenic media, CPS ID2 ( bioMerieux, 
Hampshire, UK ). The plate was incubated for 24 hrs at 37
0 
C. Bacterial colonies were 
identified by colour change and size. The result was taken as positive if greater than 10
5
 
colonies generated per ml after 24 hrs culture.   
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5.8   Cytocentrifuge 
5.8.1   Shandon Cytospin™ 2  
Principle 
This centrifuge is used to concentrate the cells from either small volumes of urine or from 
centrifuged samples with negligible cell content. The cells are concentrated into a small area 
on a glass slide with the excess fluid absorbed onto a cardboard filter. 
 
A small amount of urine, approximately 5 drops, is placed in either disposable or reusable 
cuvettes, which fit into a sealed, removable rotor head. The cuvettes must always be loaded 
inside the safety cabinet and the rotor head must always remain sealed outside the safety 
cabinet.   
Equipment 
Shandon Cytospin™ 2 
(Woodley Equipment Company LTD, Bolton, UK)  
 
Procedure 
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1. The slides were labelled with the patient’s study number. 
2. After assembling, the slide, white cardboard filter and cuvette were clipped together 
using the metal holder ensuring that the hole in the cuvette lined up with the hole in 
the filter. 
3. The cuvette assemblies were placed in the rotor head in the slots provided, ensuring 
that they balanced, using a dummy assembly as required. 
4. A disposable plastic pipette was used to place five drops of urine into the base of each 
cuvette assembly. This procedure was performed in the safety cabinet. 
5. The rotor head was closed and transferred the sealed assembly to the Cytospin. 
Operation 
The sealed rotor head was placed in the Cytospin and the lid was closed to run at 850 rpm for 
5 minutes using HI acceleration. 
Health and safety 
 
 Equipment should always be used according to the manufacturer' instructions. 
 Safety devices must always be used and never overridden. 
 In the event of failure, the fault must be reported immediately and the equipment 
taken out of use. 
 Any electrical work on equipment should be performed by a competent electrician i.e. 
someone from the works department or a service engineer. 
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Disinfection 
The interior working parts and operating panel of each centrifuge was wiped with 
hypochlorite once a week. Any reusable equipment e.g. cuvettes was immersed in 
hypochlorite overnight.  
Spillage was cleaned and the area wiped with hypochlorite according to the disinfection 
policy. 
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5.9   Stains 
The following 2 stains were used which is described in detail  below –  
 
5.9.1   May Grunwald Giemsa Stain (MGG) (180) –  
 
Principle – It gives a good nuclear and cytoplasmic differentiation. Nuclei stain purple and 
cytoplasm stain gray to blue. 
 
Methods – The cytospun slide was stained with 50 % May Grunwald (Sigma-Aldrich, St. 
Louis, USA) and then rinsed in distilled water, counterstained with 10 % Giemsa solution for 
20 minutes and then finally rinsed in buffer (phosphate buffer tablet - pH 6.8, mix in 1 litre of 
distilled water - Sigma-Aldrich, St. Louis, USA) for 30 seconds. It was then dried on a hot 
plate ready to be mounted with a cover slip. 
 
Health and safety – 
Methanol in MGG stock solution is highly flammable and toxic 
 
5.9.2   Pap stain – Papanicolou stain (181)  
 
Principle – It is a polychrome staining method, which depends on degree of cell maturity and 
cellular metabolic activity. The three main advantages of this staining procedure are: 
(1) Good definition of nuclear detail. 
(2) Cytoplasmic transparency. 
(3) Indication of cellular differentiation of squamous epithelium. 
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Methods – The various agents were placed in the different chambers in the Shandon 
Varistain-24-3 staining machine. This was then run though a prefixed programme to produce 
a correctly Pap stained slide. The programme of staining is described below –  
 
Station Reagents  Memory A 
  
1 80% Alcohol Pass  
2 70 % Alcohol Pass 
3 50 % Alcohol 5 sec 
4 Tap water 5 sec 
5 Harris Haematoxylin 2 min 30 sec 
6 Tap water 45 sec 
7 0.25% Acid water 10 sec 
8 Tap water 3 min 
9 95% Alcohol 20 sec 
10 OG 6 2 min 
11 95% Alcohol 20 sec 
12 EA 50 3 min 
13 95% Alcohol 20 sec 
14 Isopropanolol 60 sec 
15 Xylene 30 sec 
 
Items required – Prepared cytospun slide, cover slip, sterile pipettes, various % of Alcohol, 
0.25% Acid alcohol, Haematoxylin, EA50, OG 6, Xylene, Canada balsam and slide warmer 
(Sigma-Aldrich, St. Louis, USA). 
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Health and safety 
 OG 6 is flammable, toxic and irritant 
 EA 50 is flammable and oxidising agent 
 Alcohol and Isopropanolol is also flammable and oxidising agent 
 Acid water is irritant and corrosive 
 Xylene is flammable, toxic and is narcotics if used in high dosage. It is also harmful 
by ingestion and inhalation. 
 
5.9.3   Reading Stained Slides 
Once the cytospun urine sediment was obtained, it underwent Giemsa and Pap staining. For 
quantification purposes, the inflammatory cells i.e. neutrophils and lymphocytes in the 
Giemsa stained slides were counted over the whole field. Similarly the Pap stain slides were 
counted for the whole of the stained area to quantify the different urothelial cells including 
metaplastic squamous cells. The slides were examined under light microscope using a x20 
objective with x10 eyepiece. 
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5.10   Flexible Cystoscopy  
The procedure was explained to the patient and an informed consent was obtained. All the 
patients were willing to undergo a bladder biopsy so as to provide a gift of bladder tissue for 
research purposes. The procedure was performed by the researcher and by a colleague 
engaged in parallel research. 
 
Procedure 
A chlorhexidine cleaning solution and local anaesthetic – 2 % lignocaine gel (Care Fusion, 
Basingstoke, UK) were used to disinfect, numb and lubricate the urethra to make the passage 
into the bladder as comfortable as possible. A cystoscope (Dantec Medical, UK) was inserted 
into the bladder via the urethra. Attached to the instrument was a telescopic lens, a light 
source and a bag of sterile water to fill the bladder so that the bladder wall could be inspected. 
Once the instrument was in place, the examination took only few minutes to complete. The 
majority of the patients were undergoing intravesical injections of Botox, which was 
administered after the biopsy. The injections took about 20 minutes. 
.  
Most patients experienced slight discomfort during the procedure a minority found it painful. 
Practice and allowing more time for local anesthetic activity reduced the experience of pain. 
Once inspection, biopsy and the Botox injection were complete, the instrument was removed, 
and the patients were informed of the findings and the need for any further management.  
 
A nurse remained with the patient throughout the procedure.  
 
Side effects and risks  
There are potential complications with any procedure. Although rare, it is important to be 
aware of them.  
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Common  
 Mild burning or bleeding on micturition, which settles down itself.  
Occasional  
 Infection of the bladder requiring antibiotics.  
Rare  
 Delayed bleeding secondary to infection requiring antibiotics or catheter insertion 
with irrigation to remove clots.  
 Injury to the urethra.  
 Urinary retention post procedure requiring temporary insertion of a catheter.  
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5.11   Bladder biopsy specimens 
The bladder sample was removed during local anaesthetic flexible cystoscopy. 2 sets of 
bladder biopsy sample were taken from the dome of the bladder, after the informed consent 
of the patient. There was no need to apply diathermy to stop bleeding, as the samples were 
small and shallow having been taken with a flexible cystoscope. Both samples were collected, 
as the bladder mucosa was utilised. One of the biopsy samples was stored in formalin 
solution and sent for routine histology after H&E staining and the other biopsy sample was 
stored in 1.5 % glutaraldehyde solution and sent for Transmission Electron Microscopy.  
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5.12   Preparation of tissue for H & E stained Histology slide  
Procedure 
Reception of specimen 
The sample was transferred from the theatre to pathology laboratory where various checks 
were undertaken to make sure that the details from the specimen matched with the request 
form. The specimen was given an electronic number so that the details could be retraced from 
the computer database. Because the processing of these specimens formed a part of patient 
care it was required by the pathology department that the specimens be processed for 
histology by trained pathology technicians. However, the researcher did witness the process, 
was informed of the methods used and could accomplish them. 
 
Cutup stage 
The macroscopic description of the bladder biopsy specimen was recorded at this stage 
including dimensions, colour pigmentation and any artefact. 
 
Processing of the specimen 
The tissue was processed in a Vacuum Infiltration processing machine (VIP), which takes 12 
hours. Here the principle is dehydration of tissue with alcohol and xylene. The tissue 
specimen was the subject to various agitation mechanisms whereby the tissue was 
impregnated with paraffin wax a biocompatible material, which gave a firm structural support 
matrix to the tissue. 
 
 
 
 
 98 
Embedding 
The tissue was orientated in a particular manner to achieve maximum visibility upon slicing 
the tissue. It was then embedded in 60
0
 C molton paraffin wax and a cassette was placed on 
top to create a block 
 
The blocking cut stage 
The surgical block was matched to the appropriate form and the surgical number. Standard 
laboratory quality control was conducted. Because these specimens were part of clinical care 
they had to be prepared by certified NHS laboratory technicians 
 
Microtomy 
The tissue was expertly cut at 4 µm (thickness of one cell) and creases eliminated by floating 
the slice in a 35
0
 C water bath and then trapping the slice on a glass slide which had 
previously been numbered correctly. The slide was then dried on the hot plate at 60
0
 C for 10 
minutes. 
 
Staining of slide - H & E 
The slides were processed by a staining machine for the Haematoxylin and Eosin stain (H & 
E) (Sigma-Aldrich, St. Louis, USA), which took 15 minutes. The wax in the slides was 
melted in a 50
0
 C oven, with further dewaxing by dipping in a series of solutions of xylene 
and alcohol followed by a water wash. The slide was then stained by Haematoxylin to define 
cellular constituents of tissue (e.g. Chromatin). This was then differentiated in acid/alcohol to 
give sharp nuclear stain. Then the slide was plunged into water and counterstained with eosin 
(for cytoplasm).  The tissue was again dehydrated via various strengths of alcohol and finally 
washed with xylene, which helped the coverslip to adhere.  
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Coverslip 
The adhesive Dpx was used which has the same refractive index as the microscope (1.5). 
The slides were reviewed by the researcher, supervisor and the histopathologist. 
 
Health and Safety  
 Alcohol is flammable 
 Xylene is flammable, toxic and irritant 
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5.13   Preparation of tissue for Transmission Electron Microscopy 
 
Procedure 
The electron microscopy services were insistent that the tissue be prepared by trained 
technicians because of the need to ensure quality of the product. 
 
The tissue was fixed in 1.5 % paraformaldehyde/1.5 % glutaraldehyde in phosphate buffer, 
washed with phosphate buffered saline [Oxoid] and postfixed using 1 % osmium tetroxide / 
1.5 % potassium ferricyanide, washed with distilled water and dehydrated using graded 
alcohols 30 %, 50 %, 2 x  70 % and 3 x 100 %, followed by infiltration with 50 % alcohol / 
50 % Lemix (TAAB) epoxy resin mixture overnight and the next day infiltrated with 100 % 
Lemix resin for a minimum of 6 hours, followed by polymerisation at 70
0
 C overnight. 
  
Sections were cut on a Reichert-Jung ultracut E microtome and collected on 300HS, 3.05mm 
copper grids (Gilder). The sections were stained with saturated uranyl acetate in 50 % ethanol 
(TAAB) and Reynolds lead citrate. 
 
Sections were viewed and photographed using a Philips CM120 transmission electron 
microscope (John Hopkins, Baltimore, USA). This was reviewed by the electron microscopist, 
researcher and the supervisor. 
 
Reagents 
Glutaraldehyde 
(20mls 20 % paraformaldehyde [Analar BDH] + 16mls 25 % glutaraldehyde [TAAB] + 59 
mls phosphate buffered saline [Oxoid]) 
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Osmium tetroxide 
1 % osmium tetroxide [Analar BDH] + 1.5 % potassium ferricyanide [BDH] in PBS [Oxoid] 
 
Toluidine blue stain 
1 % toluidine blue [Raymond Lamb] with 0.2 % pyronine [Raymond Lamb] in 1 % sodium 
tetraborate [Analar BDH]. 
 
Reynolds lead citrate 
Dissolve 1.33g lead nitrate [BDH] in 15mls distilled water and 1.76g sodium citrate [BDH] in 
15mls distilled water, mix solutions together and dissolve the resulting precipitate with 8 mls 
of 1M sodium hydroxide [BDH], make up to final volume of 50mls 
 
Lemix epoxy resin 
Lemix A (25mls) + Lemix B (55mls) + Lemix D (20mls). Pour into plastic resin bottle and 
add 2 mls of BDMA, mix well. 
 
Health and Safety 
 Glutaraldehyde - Harmful by inhalation. Harmful if in contact with skin. Prolonged 
skin contact may cause dermatitis. 
 Osmium tetroxide - Harmful by inhalation and if swallowed. Corrosive to eyes and 
skin causing burns. Stains skin black.  Low concentrations of vapour affect the eyes.  
Use only in a fume cupboard 
 Potassium ferricyanide - Low toxicity. May be harmful if ingested in large quantities. 
Irritating to eyes, respiratory system and skin 
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 Alcohol 74OP  - Flammable. Toxic by inhalation, in contact with skin and if 
swallowed. 
 LEMIX A - Mild skin and eye irritant. 
 LEMIX B - May cause slight irritation to eyes and skin. Low toxicity. 
 LEMIX D - Harmful by ingestion, inhalation and skin contact. May be irritating to 
skin and eyes. 
 BDMA - Irritating to eyes, skin and respiratory system. Harmful by ingestion. 
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5.14   Light Microscopy 
A light microscope is a sophisticated optical instrument that provides high-resolution images. 
The four basic components of a microscope addresses resolution, illumination, magnification 
and imaging. An Olympus CX41 Light Microscope was used to count the cells using x20 
objective with x10 eyepiece (GX Optical, Suffolk, UK). 
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5.15   Statistical Analysis  
The data were checked for normality using Q-Q plots and by histograms. Normally 
distributed data were analysed using the parametric method for comparing means - ANOVA. 
 
Where the distributions were found to be non-normal no attempt was made to transform by 
logarithmic conversion because the data consisted of discontinuous counts of cells. Therefore 
non-parametric tests of significance were achieved. Where comparison between two groups 
was being achieved the Mann-Whitney U test was used. In circumstances where more than 
two groups were compared the Kruskal-Wallis H test was used. In all cases the 95 % level of 
confidence was used (alpha=0.05). The data distributions were shown on graphs as the 
medians with 95 % confidence intervals. 
  
Ordinal data were analysed in contingency tables using the Chi-square (Χ2) test at the 95 % 
level of confidence (α=.05) 
 
It was not possible to calculate a suitable sample size at the inception of this study because 
the subject matter was so inchoate. It was therefore thought best to sample within the limits 
of patient availability, consent and time.  
 
Giemsa Stain – In the event with a mean total inflammatory cell count of 29 (sd=33) in 178 
patients and the same in 21 controls with 6 (sd=5.6), this study had 100% power at alpha of 
5%, so that the probability of a type II error was vanishingly small when the probability of a 
type I error was 0.05. 
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Pap Stain – Similarly with a mean deep transitional cell count of 67.27 (sd=162) in 157 
patients and the same in 29 controls with a mean deep transitional cell count of 18.86 
(sd=18.36), this study had a 97.6% power at alpha of 5%. 
 
Histopathology and Electron Microscopy – It was not possible to calculate the sample size for 
this study as the subjects were few in numbers, especially the controls. 
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5.16   Experience of Methods 
This section provides an operational account of the application of the methods and the 
experiences that resulted.  
 
5.16.1    Sampling and Recruitment of patients 
As the patients were recruited from the Incontinence clinic at the Department of Medicine, 
Whittington Campus, UCL Medical School there is some overlap of patients providing the 
urine sample for different analysis. There was no random selection of patients but the 
samples and data were collected consecutively from those attending the Incontinence clinic. 
The stringent recruitment criteria which were applied during the screening made it essential 
that all comers were considered for inclusion in the study if the study was to achieve the 
necessary sample sizes. The normal controls were obtained from the hospital staff and the 
medical students. It was essential to have control data from persons without any symptoms at 
all, including no nocturia and it was found more pragmatic to obtain such from groups who 
could clearly understand the strictures rather than general population. We had already 
discovered the cost and time demands of finding normal controls randomly in the general 
population. 
 
5.16.2   Urine Collection  
The CSU collection was a part of the routine patient care but nevertheless there were a few 
occasions when patients refused to provide with a sample at all or were insistent on providing 
only MSU. These persons were not included in our study. Because of ethical problems a 
MSU from the normal controls had to be obtained, although a small number of CSU’s could 
be obtained from patients undergoing gynaecological procedures. The controls providing the 
MSU’s were carefully instructed in the production of a meticulous MSU and many already 
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clearly understood the principles. The moment urine was collected; 5 ml of the sample was 
mixed with 5 ml of 70 % alcohol immediately to help preserve the cells and to achieve better 
Cytospin™ preparation. At times there was very little urine collected in the sample, this was 
especially the case when collecting CSU’s. If the urine volume was less than 5 ml, it was not 
included in the study because of the very high risk of contamination. The CSU/MSU was sent 
for routine culture to the laboratory as soon as possible, within 3 hours. On 2 occasions the 
laboratory was unable to process the culture request because of urine leakage from the 
specimen pot. Because the samples were anonymised for processing through research 
methods, utmost care was needed to avoid any mismatch of labels on the urine sample pots. 
 
5.16.3   Cytospin™ Preparation 
The researcher took some time and considerable practice before achieving entirely 
satisfactory urinary sediment preparations, and ultimately that depended on the Cytospin™ 
equipment. Initially researcher took 10 ml of urine which was centrifuged at 2000 rpm for 6 
minutes. The supernatant fluid was discarded and the sediment was spread manually over a 
glass slide with another glass slide. Despite many hours the researcher was unable to achieve 
reliably, a single cell layer preparation. The stacking of cells on the slide prevented from 
obtaining an even stain of the preparation. This was presented to the cytologists at this centre 
who suggested the use of the Shandon Cytospin™ 2. A second-hand device was purchased 
and after some practice the researcher began to achieve beautiful single-layer cell 
preparations very consistently. These proved very well to be able to take up the various stains 
evenly. Initially single frosted slides were used but then chose to use super frosted versions 
since these are known to be made of a higher quality glass and thereby result in a much 
clearer image. It was extremely important to store the slides in closed, clean containers before 
use because they had a tendency to attract contaminants onto both surfaces.   
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5.16.4    Staining 
The staining was an essential part of this experiment and it was vital to get it correct. The 
Giemsa stain was used to describe the differential morphology of white cells discriminating 
lymphocytes and polymorphonuclear leucocytes. The Pap stain was used for a different 
purpose in that it permits proper discrimination between epithelial cells. Whilst the Pap stain 
is taken up by inflammatory cells so that they are indentified as contrasting from epithelial 
cells they look very similar and it is not possible to discriminate lymphocytes from 
polymorphs. Initially, the Pap stain was used manually but found to be extremely difficult to 
achieve uniform results and felt that the interpretation could not be accepted as reliable. 
Therefore; the manually stained slides were not included in the analysis. In order to overcome 
the problem of consistency a Shandon Varistain machine was obtained. This has the capacity 
to achieve a number of automated staining protocols.  Once a defined programme had been 
entered into the machine it proved well able to achieve very consistently stained Pap slides 
with sets of slides being processed in bulk. There were instances when machine got stuck and 
sometimes faulty transitions caused slides to break, in which case replacement preparations 
were made up and processed. The Giemsa staining was done manually since it involved 
fewer steps and provided very consistent results without any need for automation.  
 
5.16.5    Reading slides 
Once the slide was stained, they were fixed with a cover slip mounted using Canada balsam. 
The slides were then examined under a light microscope in order to evaluate the nature of the 
cells and to count them. This proved to be the most difficult task and proved to be the most 
time-consuming. The cells over the whole circle of sediment were counted. This required 
several traverses of the slide surface and particular concentration to ensure that the traverse 
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was not duplicated by accident. On an average, it took an hour to read a slide for each of the 
stains. It took a considerable amount of practice to become proficient at focusing on the field 
of interest as paucicellular preparations could demand a high level of persistence before the 
counting zone was assimilated. The area of interest was a circular area in the centre of a slide 
which was 5 mm in diameter. It was found that if the counting zone area was encircled with a 
red marker pen it became much easier to get the bearings. In order to be consistent the slide 
was moved so that the objective sampled in traverses of the vertical plain, going from top to 
bottom then bottom to top, thus sampling columns as it moved across the slide from left to 
right.  
 
It soon became evident that the consistency of the Cytospin™ machine meant that the spun 
circles of sediment offered the opportunity of semi-quantitative analysis of the cells. Initially 
morphological distribution counts of samples of 100 cells, was tried. However, it was found 
out that some slides had fewer than 100 cells in the sediment area whereas others had well in 
excess. This meant that a limit of 100 cells counting imposed an arbitrary maximum 
achievable total. It was therefore decided to count all of the cells in the circle of sediment 
thereby producing a meaningful total cell count along with a differential analysis. At the time, 
it was not expected that the total cell count to exhibit between disease state differences. It was 
assumed, falsely as it turned out, the differential ratios would be the salient elements. 
 
5.16.6    Flexible cystoscopy and Bladder biopsy 
As most of the patients were undergoing Botox injection at the time of providing bladder 
biopsy, the procedure lasted for approximately 20-25 minutes. At first it was found that a few 
patients reported pain when the biopsy was obtained. Thereafter the method was modified so 
as to wait for an extra five minute after instilling 2% lignocaine gel into the urethra. From 
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that time, the procedure was better tolerated although complete avoidance of some discomfort 
could not be achieved. The probability of this was made clear in the patient’s information 
sheet, and very grateful to the patients who agreed to this biopsy for research purposes. The 
biopsy destined for routine histology after H&E staining was collected in formalin solution. 
The biopsy for electron microscopy was initially collected in the normal saline for immediate 
transfer to the EM laboratory. This process was then modified so that the specimen was 
collected into glutaraldehyde solution which preserved the specimen thereby obviating the 
need for immediate transportation.  
 
An interesting experience arising out of this work was that initially the histopathologist 
challenged the utility of a superficial bladder biopsy. It transpired that their appreciation of 
this process was that it was deployed to seek out evidence of malignancy. Surprising though 
this may be, it turned out that the notion of taking an urothelial sample in order to look for 
evidence of inflammation and reactive urothelial changes was a novel notion. In fact up to 
that point the reports had been classifying biopsies as “normal” if no malignancy or dysplasia 
was seen. When archived slides classed as “normal” were reviewed, in many cases  
inflammatory infiltrates were identified. An engaging consequence of this work is that 
routine histological reporting of urothelial specimens has changed at this centre. 
 
5.16.7    Interpretation of Histology slides  
Once the procedure with the histopathologist was agreed, the researcher examined the slide 
preparations with his supervisor. The slides were examined and reported independently of 
each other. Had it been different outcomes a consensus view was negotiated. In the event a 
divergent view never occurred. Having recorded the findings these were cross-checked with 
those provided by a histopathologist. The fact that there was an agreement, it demonstrates 
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the very straightforward nature of the inflammatory changes observed. In particular normal 
preparations looked very different from those exhibiting inflammation in this series. 
 
When these analyses had been completed, the slides were crosschecked with another 
consultant histopathologist at a different hospital. 
 
5.16.8    Interpretation of Electron Microscopy slides 
The methods section described the preparation of the epoxy resin fixed slides used for EM. 
An experienced electron microscopist prepared sets of photomicrographs obtained from the 
sections relevant to each biopsy. The EM pictures confirmed the appearances that had already 
been described by light microscope. The only novel observation, additional to that, which 
could not be seen under light microscopy, was an apparent thickening of the basement 
membranes of the urothelium obtained from patients with OAB. Because of the difficulties in 
obtaining bladder biopsy material from normal controls, the biopsies were taken from 3 
persons with no symptoms and normal controls but one of the samples was too small for 
processing so EM photomicrographs were obtained from two controls.  
 
There were 100 different measurements taken to assess for basement membrane thickening 
and the average was recorded. To maintain the standard measurement all the 
photomicrograph with a magnification of x8800 were included. 
 
5.16.9    Quality Assurance 
This was particularly important for Giemsa and Pap stain slides. There were approximately 
400 slides, which were subjected to total cell count of different morphological origin 
depending on the type of stain used. This was extremely laborious and time consuming as 
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each slide took approximately an hour to read and considerable practice to be able to 
recognise the various cells. It would be very difficult to find someone to review all the 400 
slides.  
Therefore random samples of slides were reviewed to ensure quality control. 
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RESULTS 
The patients attending the Incontinence clinic at the Department of Medicine, Whittington 
Campus, UCL Medical School were recruited for the study. This study involved the 
deployment of 4 different methods for evaluating the inflammatory reactions associated with 
symptoms of OAB. The methods were applied to samples of different numbers of patients but 
there was some overlap so that patients could contribute data into more than one method.  
 
(1) The first data set was obtained from 246 patients, 234 females (95 %) and 12 males (5 %), 
mean age of 57 (range 22-91), sd =19, with symptoms of OAB. These patients provided a 
catheter specimen of urine, which was processed so as to provide Cytospin preparation. 
Initially the slides were stained by the Pap method and subsequently, when differential white 
cell analysis was required, the Giemsa stain was adopted. 89 Patients provided Pap and 
Giemsa stained samples; the other 157 patients provided either a Pap preparation or a Giemsa 
version. Thus 178 patients provided Giemsa preparations and 157 Pap stained slides. 
 (See flow chart below) 
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CHAPTER 6 
RESULTS 
 
The patients attending the Incontinence clinic at the Department of Medicine, Whittington 
Campus, UCL Medical School were recruited for the study. This study involved the 
deployment of 4 different methods for evaluating the inflammatory reactions associated with 
symptoms of OAB. The methods were applied to samples of different numbers of patients but 
there was some overlap so that patients could contribute data into more than one method.  
 
(1) The first data set was obtained from 246 patients, 234 females (95 %) and 12 males (5 %), 
mean age of 57 (range 22-91), sd =19, with symptoms of OAB. These patients provided a 
catheter specimen of urine, which was processed so as to provide Cytospin preparation. 
Initially the slides were stained by the Pap method and subsequently, when differential white 
cell analysis was required, the Giemsa stain was adopted. 89 Patients provided Pap and 
Giemsa stained samples; the other 157 patients provided either a Pap preparation or a Giemsa 
version. Thus 178 patients provided Giemsa preparations and 157 Pap stained slides. 
 (See flow chart below) 
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Flow Chart 
                                                             246  
 
(Total patients providing urine samples) 
 
                     89         157 
         (Patients provided sample for both)            (Patients provided either sample) 
  
                      89                             68 
       (Provided sample for Giemsa)   (Provided sample for Pap) 
 
 
       178                               157 
 (Total Patients for Giemsa)                        (Total Patients for Pap)  
 
(2) The second data set was obtained from 79 patients, 66 female (84 %) and 13 male (16 %), 
mean age 56 (range 25-81), sd=15, with OAB symptoms. They provided bladder biopsies for 
paraffin block section, H&E stained, histology. The majority of these patients donated a 
biopsy at the time of intravesical Botox injection for OAB. 
 
(3) The third data set was obtained from 22 patients all of whom were suffering from OAB.  
18 of these also contributed bladder biopsies for the H&E histology data set. This third group 
provided biopsies for electron microscopic analysis (EM) analysis. This sample consisted of 
16 females (73 %), 6 males (27 %) and their mean age was 50 (range 27-71), sd=13. 
 
(4) 43 normal controls provided urine samples; 36 MSU and 7 CSU. 21 samples provided 
Giemsa preparations and 29 provided Pap stained preparations. The 7 CSU samples were 
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used to achieve Pap and Giemsa slides. This sample consisted of 24 females (56 %), 19 males 
(44 %) and their mean age was 33 (range 20-64), sd=10. 
 
5 normal controls (all males) provided bladder biopsies for histology and 2 normal controls 
(all males) provided biopsies for EM comparisons. It was extremely difficult to recruit 
normal controls for the experiments that required biopsy. Whilst many patients undergoing 
routine cystoscopy were very happy to offer biopsies for research purposes, finding those 
without urinary symptoms was the key impediment. Though the demographics were different 
between the control and the patient group, as the controls were all males and younger than the 
patient group but utmost care was taken to make sure they were devoid of lower urinary tract 
symptoms and their urine was  free of pyuria and urine culture clear. 
 
These patients and controls were characterised according to their symptoms and whether or 
not they exhibited pyuria ≥1 wbc μl-1. Since all of the controls showed zero pyuria they 
provided a single clinical description. In the patient groups all had symptoms of OAB some 
with pyuria ≥1 wbc μl-1 and some without. 
 
Whilst all the controls were significantly younger than the patients, the 2 patient groups, 
OAB symptoms zero pyuria and OAB symptoms & pyuria ≥1 wbc μl-1, did not differ in 
respect to age, sex and symptoms; frequency, incontinence and urge score. This is further 
described in details in individual section. 
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6.1   Giemsa staining Results 
The aim of this study was to examine the differential inflammatory cell count in the cytospun 
preparation from patients with OAB symptoms compared with normal controls. The patients 
with OAB symptoms were further sub-classified on the presence or absence of pyuria ≥1 wbc 
μl-1 as OAB symptoms & pyuria or OAB symptoms zero pyuria.  
 
In total, 178 patients with OAB symptoms (94 % female) and 21 controls (76 % female) were 
studied. The controls were younger (mean age 34, 95 % CI 30 to 38, sd=9) as compared to 
patients with OAB symptoms (mean age 57, 95 % CI 54 to 60, sd=19). The age distribution 
is shown in figure 6.1.  
 
Figure 6.1 – The mean age with 95 % CI for the experimental groups 
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The distributions of the symptoms of frequency, urgency and incontinence were checked for 
normal distributions using Quantile-Quantile (QQ) plot available in SPSS and found to be 
appropriately normal and ANOVA was used to analyse the between group differences.  
 
The patients with OAB symptoms & pyuria ≥1 wbc μl-1 reported an average 24-hour 
frequency of 10 (sd=6, 95 % CI 8 to 12) and average 24-hour incontinence of 1 (sd=2, 95 % 
CI 1 to 2). Their mean urgency score was 5 (sd=5, 95 % CI 3 to 6), whereas patients with 
OAB symptoms zero pyuria reported an average 24-hour frequency of 8 (sd=4, 95 % CI 7 to 
10) and average 24-hour incontinence of 1 (sd=2, 95 % CI 1 to 2). Their mean urgency score 
was 4 (sd=3, 95 % CI 3 to 5).  
 
Formal comparisons of the two groups OAB symptoms & pyuria ≥1 wbc μl-1 and OAB 
symptoms zero pyuria, showed no significant differences in symptoms: 24-hour frequency 
( p=0.056, 95 % CI of difference -0.1 to 5), 24-hour incontinence (p=0.406, 95 % CI of 
difference -1 to 0.5) and urgency score (p=0.532, 95 % CI of difference -2 to 1). 
 
Despite the differences in age and gender the symptoms of the MSU group did not differ 
from those of the CSU group. 
 
CSU group: Average 24-hour frequency = 9 episodes (sd=5); average 24-hour incontinence = 
1episodes (sd=2); mean urgency score = 4 (sd=4)  
 
MSU Group: Average 24-hour frequency = 6 episodes (sd=1); average 24-hour incontinence 
= 0 episodes, sd=0; mean urgency score = 1 (sd=0)  
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Comparisons 
24-hour frequency: p=0.257, 95 % CI of difference -9 to 2 
24-hour incontinence p=0.286, 95 % CI of difference -3 to 1  
Urgency score p=0.152, 95 % CI of difference -7 to 1  
 
Analysis of cell counts 
The data describing the cell counts were first checked for normality using the Quantile-
Quantile (QQ plot available in SPSS. It was shown that these data were far from normally 
distributed. Figure 6.2 illustrates the QQ plot and if the data were normally distributed the 
points would fall juxtaposed to the linear function plotted for comparison. The lie of the data 
points show that the experimental data deviate substantially from the ideal.  
 
Because of this, non-parametric tests were used for the analysis. There were 3 groups; (1) 
controls, (2) OAB symptom zero pyuria and (3) OAB symptom & pyuria ≥1 wbc μl-1 so the 
Kruskal-Wallis test was used and the test statistic H was recorded along with the degrees of 
freedom (=2) and p value. The data distributions were illustrated by plotting the median count 
and 95 % CI of the median which were calculated by using the statistical package Minitab. 
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Figure 6.2 – Normal QQ plot of the Total White cell count 
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In the above graph, the X axis shows total inflammatory cell count and the green 
perpendicular line suggest the expected normal lie of the data, and the linearity of points 
(small red boxes) suggests that the data are not normally distributed. 
 
75 of 178 (42 %; 95 % CI = 36 % to 48 %) patients with OAB symptoms showed pyuria ≥1 
wbc μl-1. 103 of 178 (58 %; 95 % CI = 50 % to 65 %) patients did not show pyuria zero wbc 
μl-1. None of the 21 controls had pyuria ≥1 wbc μl-1. As has already been described, the 2 
OAB symptom groups were similar in age & sex.  
 
Because of the decision to identify pyuria as ≥1 wbc μl-1 for the purpose of this thesis, a sub-
analysis was conducted on these data to check for differences between Pyuria = 0 wbc μl-1, 
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pyuria = 1 to 9 wbc μl-1 and pyuria ≥10 wbc μl-1.There was a difference in urine culture 
results (Χ2 =34, df=2, p<0.001). 
 
7 of 103 (7 %) of OAB zero pyuria were positive. 
4 of 30 (13 %) of OAB & pyuria < 10 (1 to 9 wbc µl
-1
) were positive. 
21 of 45 (47 %) of OAB & pyuria ≥10 µl-1 were positive. 
1 of 21 (5 %) of controls was culture positive. 
 
There were significant differences between all the groups in the number of neutrophils, 
lymphocytes and therefore the total white cell counts. These are shown in figures 6.3 to 6.5. It 
can be seen that as might be expected, the patients with OAB and pyuria ≥1 wbc μl-1 stand 
out. However it should also be noted that OAB patients without pyuria had significantly 
higher inflammatory cell counts in their spun sediments than did normal controls. This 
implies that the Cytopsin method is unmasking an inflammatory reaction in the urine of OAB 
patients that would not be detected by ordinary microscopy of the urine.  
 
 
 
 
 
 
 
 
 
 
 122 
Figure 6.3 – The median Neutrophil count and 95 % CI between groups 
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Figure 6.3a – Picture of Neutrophil  
(Olympus light microscope, X20 Magnification, Giemsa stained slide) 
 
 
Polymorphonuclear 
leucocytes (neutrophils) 
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Figure 6.4 – The median Lymphocyte count and 95 % CI between groups 
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Figure 6.4a – Picture of Lymphocyte 
(Olympus light microscope, X20 Magnification, Giemsa stained slide) 
     
 
 
 
Lymphocytes 
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(Olympus light microscope, X20 Magnification, Giemsa stained slide) 
 
 
 
 
 
Figure 6.5 – The median total white cell count and 95% CI between groups 
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The results of the Kruskal-Wallis test for these three analyses were as follows: 
Neutrophils  H=28 df=2 p<0.001 
Lymphocytes  H=38 df=2 p<0.001 
Total white cells H=36 df=2 p<0.001 
 
An analysis of the ratio of the lymphocyte:neutuophil count was conducted on the 2 OAB 
symptom groups. It was found that the lymphocyte:neutrophil ratio differed between OAB 
symptom Groups: 1:1 in OAB symptom zero pyuria but 2:3 in OAB symptom & pyuria ≥1 
wbc μl-1 (H=12, df=1, p=0.001). 
 
A further sub-analysis was carried after removing the patients whose urine culture were 
positive. A total of 146 patients; 93 OAB with zero pyuria (64 %) and 53 OAB & pyuric ≥1 
wbc μl-1 (36 %) were identified. Their mean age, sex, neutrophil count, lymphocyte count and  
the Total inflammatory cell count were almost similar to the above statistical calculations, if  
not were slightly higher. Infact their ratio of  lymphocyte:neutrophil were also similar. The  
OAB & pyuria ≥1 wbc μl-1 group showed much higher all the counts as compared to OAB  
with zero pyuria, which in turn showed higher counts than the control group. 
 
The control group data was also similar as only 1 out of original 21 had to be excluded due to 
positive culture. 
 
It was a conscious decision not to replicate all the statistics, graphical and numerical 
calculations. 
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6.2   Pap staining Results 
The Pap stain experiments were designed to examine the differential urothelial cell counts by 
enumerating; umbrella cells and deep transitional cells and to seek metaplastic squamous 
cells. The hypothesis being tested was that chronic urothelial stress and inflammation should 
be associated with increased urothelial cell turnover and squamous metaplasia. If such 
changes were not identified then some doubt would be felt about to the proposition that the 
persistence of pyuria ≥1 wbc μl-1 in OAB  implied significant chronic cystitis. Urine samples 
were processed through a Shandon Cytospin™ and then stained by the Pap method. 
Preparations from patients with OAB symptoms were compared with those from normal 
controls.  
 
The patients with OAB symptoms were further sub-classified on the presence or absence of 
pyuria ≥1 wbc μl-1 as OAB symptoms & pyuria or OAB symptoms zero pyuria. 
 
In total 157 patients with OAB symptoms (97 % female) and 29 controls (48 % female) were 
studied. The controls were younger (mean age 33, 95 % CI 28-38, sd=12) as compared to 
patients with OAB symptoms (mean age 54, 95 % CI 51-59, sd=19). The age distribution is 
shown in figure 6.6. 
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Figure 6.6 – The mean age with 95 % CI for the experimental groups 
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The patients with OAB symptoms & pyuria ≥1 wbc μl-1 reported an average 24-hour 
frequency of 10 (sd=5, 95 % CI 8 to 13) and average 24-hour incontinence of 1 (sd=2, 95 % 
CI 0.5 to 2). Their mean urgency score was 5 (sd=5, 95 % CI 3 to 8), whereas patients with 
OAB symptoms zero pyuria reported an average 24-hour frequency of 10 (sd=8, 95 % CI 8 to 
12) and average 24-hour incontinence of 1 (sd=2, 95 % CI 0 to 1). Their mean urgency score 
was 4 (sd=3, 95 % CI 3 to 5).  
 
Formal comparisons of the 2 groups, OAB symptoms & pyuria ≥1 wbc μl-1 and OAB 
symptoms zero pyuria showed no significant differences in symptoms: 24-hour frequency 
(df=89, p=0.167, 95 % CI of difference –14 to 2), 24-hour incontinence (df=89, p=0.352, 
95 % CI of difference -3 to 1) and urgency score (df=89, p=0.503, 95 % CI of difference 3 to 
6). 
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Some patients could not provide a CSU. A comparison of age and sex between those 
providing MSU (n=4) against those providing a CSU (n=153), confirmed the predominance 
of males in the MSU group (100 %) and the fact that the MSU group was younger (mean age 
= 40, sd= 21) than the CSU group (mean age = 57, sd= 18) although, given the small numbers, 
this could not be statistically significant. For the same reasons, the symptoms of the MSU 
group did not differ from those of the CSU group. 
 
CSU group: Average 24-hour frequency = 10 episodes (sd=7); average 24-hour incontinence 
= 0 episodes (sd=0); mean urgency score = 6 (sd=4)  
 
MSU Group: Average 24-hour frequency = 4 episodes (sd=1); average 24-hour incontinence 
= 0 episodes, sd=0; mean urgency score = 6 (sd=4)  
 
Comparisons 
24-hour frequency: p=0.167, 95 % CI of difference -14 to 2 
24-hour incontinence p=0.352, 95 % CI of difference -3 to 1  
Urgency score p=0.503, 95 % CI of difference -3 to 6  
 
Analysis of cell counts 
The data describing the total cell counts were first checked for normality using the Quantile-
Quantile (QQ) plot available in SPSS. These data were not normally distributed (See figure 
6.7). Non-parametric tests were used to analyse these data. Once again there were 3 groups; 
(1) controls, (2) OAB symptom zero pyuria and (3) OAB symptom & pyuria ≥1 wbc μl-1; so 
the Kruskal-Wallis test was used and the test statistic H was recorded along with the degrees 
of freedom (=2) and p value. Similarly, the data distributions were illustrated by plotting the 
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median count and 95 % CI of the median. These were calculated by using Minitab statistics 
package. 
 
Figure 6.7 – Normal QQ plot of the Total cell count 
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In the above graph, the X axis shows total urothelial cell count and the green perpendicular 
line suggest the expected normal lie of the data, and the linearity of points (small red boxes) 
suggests that the data are not normally distributed. 
 
45 of 157 patients with OAB symptoms (29 %; 95 % CI = 22 % to 36 %) showed pyuria ≥1 
wbc μl-1. 112 of the 157 (71 %; 95 % CI = 64 % to 78 %) patients did not show pyuria. None 
of the 29 controls had pyuria. The 2 OAB symptom groups were similar in age & sex, as 
described above. 
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There were significant differences between controls and OAB symptom groups in the number 
of transitional and umbrella cells but no significant difference in the number of squamous 
cells between the groups. However, this finding should be viewed with some caution since 
76 % of the control group provided MSU samples and skin cell contamination was a 
significant risk. This is shown in figures 6.8 to 6.10. Interestingly, there is no difference in 
transitional cell count between OAB groups, even in presence of pyuria. 
 
Figure 6.8 – The median umbrella cell count and 95 % CI between groups 
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Figure 6.8a – Picture of Umbrella cell  
(Olympus light microscope,  X20 Magnification,  Pap stained slide) 
      
 
Figure 6.9 – The median transitional cell count and 95 % CI between groups 
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Umbrella cell 
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Figure 6.9a – Picture of Deep Transitional cell  
(Olympus light microscope,  X20 Magnification,  Pap stained slide) 
     
 
Figure 6.10 – The median squamous cell count and 95 % CI between groups 
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Deep transitional cell 
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Figure 6.10a – Picture of Squamous cell 
(Olympus light microscope,  X20 Magnification,  Pap stained slide) 
   
 
 
The results of the Kruskal-Wallis test for these three analyses were as follows: 
Umbrella cell   H=10 df=2 p=0.008 
Transitional cell  H=11 df=2 p=0.004 
Squamous cell   H=1 df=2 p=0.543 
 
 
 
 
 
 
 
 
 
 
Squamous cell 
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6.3   Histology Results 
The histology experiments were designed to test the hypothesis; that persistent pyuria of  ≥1 
wbc μl-1 reflected chronic cystitis in patients with OAB. The test method was direct 
visualisation of the urothelium under a light microscope.  Paraffin sections of urothelium 
were stained with H&E and scrutinised for the presence of inflammatory changes. In total 79 
patients (13 male (16 %) & 66 female (84 %); mean age 56, sd=15) with OAB symptoms, 15 
with OAB symptoms & pyuria ≥1 wbc μl-1, 60 OAB symptoms zero pyuria provided bladder 
biopsies. 4 patients provided inadequate tissue and could not be included in the analysis. 5 
normal asymptomatic controls (all males) provided bladder biopsies. 55 out of 60 OAB zero 
pyuria patients (92 %; 95 % CI = 82 % to 96 %) and 14 out of 15 OAB & pyuria ≥1 wbc μl-1 
patients (93 %; 95 % CI = 70 % to 99 %) (X
2
 = 24, df=1, p<0.001) manifest all the features 
of chronic cystitis viz; urothelial hyperplasia, mixed inflammatory cell infiltrate, 
oedema/congestion and urothelial denuding.  
 
Only 1 specimen showed the presence of a mast cell. 5 normal controls showed normal 
urothelium without any features of inflammation. The normal urothelium is 3 to 6 layers in 
thickness without inflammatory cell infiltrate and without oedema. Figures 6.1 to 6.16 depict 
this. 
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Figure 6.11 – Photomicrograph showing urothelial hyperplasia/metaplasia - Pyuria 
                (Olympus light microscope, X20 Magnification,  H & E stained slide) 
 
Figure 6.12 – Photomicrograph showing urothelial hyperplasia/metaplasia – No pyuria 
                (Olympus light microscope, X20 Magnification,  H & E stained slide) 
Hyperplastic urothelium 
Urothelial metaplasia 
 
Hyperplastic urothelium 
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Figure 6.13 – Photomicrograph showing mixed inflammatory cell infiltrate 
                 (Olympus light microscope, X20 Magnification,  H & E stained slide) 
 
Figure 6.14 – Photomicrograph showing oedema and congestion  
                                   (Olympus light microscope, X20 Magnification,  H & E stained slide) 
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 137 
Figure 6.15 – Photomicrograph showing urothelial denuding 
               (Olympus light microscope ,  X20 Magnification,  H & E stained slide) 
 
Figure 6.16 – Photomicrograph showing normal urothelium 
               (Olympus light microscope, X20 Magnification,  H & E stained slide) 
 
Urothelial denuding 
Loss of normal  
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Normal urothelium 
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6.4   Electron Microscopy Results 
The aim of this study was to assess the ultrastructure of the urothelium. Once again normal 
controls were very hard to find and could only achieve specimens from 2 out of 3 biopsies 
since one produced an inadequate tissue sample.  The EM confirmed all the features of 
chronic cystitis seen on the light microscopy, and already described in the histology results 
(fig 6.18 - 6.19). In addition, the photomicrographs of the OAB patients, irrespective or 
pyuria, demonstrated urothelial denuding and a breakdown in the bridging between urothelial 
cells. There was also a loss of cell cohesion. The same samples showed patches where the 
cells appeared darker with intact bridging. In areas of shedding the cells appeared lighter. 
None of these features were exhibited by the controls.  
 
More importantly, it was noted that the basement membrane of the OAB patients thickened in 
places (fig 6.20). There was a variance in the basement membrane thickness in patients, but 
less so in the controls. In parts the basement membrane appeared clear and uniform in other 
parts it was much less uniform with a rather fluffy inferior margin. The measurements were 
effected by making 100 thickness measurements along the extent of the section at regular 
intervals (5 microns) between measurements. The mean width was then calculated from these 
data. 
 
The slides were analysed using Philips CM120 transmission electron microscope (TEM), 
using a magnification of x8800 and the basement membrane thickness was measured using 
AMT image capture engine version 600.  
 
22 patients (6 male (27 %) & 16 female (73 %); mean age 50, sd=13) with OAB symptoms 
(15 OAB symptoms zero pyuria, 7 OAB symptoms & pyuria ≥1 wbc μl-1 and 2 normal 
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controls provided bladder biopsies for EM analysis. The basement membrane was measured 
in all of these samples.   
 
The patients with OAB showed non-uniform thickening of the basement membrane. The 
mean thickness of the basement membrane, sampled at 100 points along its length, showed a 
mean thickness of 514 nm, (sd=396) for OAB patients zero pyuria, mean thickness of 459 nm, 
(sd=354) for OAB patients & pyuria ≥1 wbc μl-1 as compared to controls with a mean 
thickness of 338 nm, (sd=246) (H=48, df=2, p<0.001). The data is illustrated in figures 6.17 
with the median and 95 % CI for each group as the comparative statistical analysis was non 
parametric because of the sample size. 
 
Figure 6.17 – The median basement membrane width and 95 % CI between 
           groups 
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Figure 6.18 – Electron micrograph showing Lymphocytes 
(Philips CM120 transmission electron microscope, X8800 magnification, epoxy resin stained slide) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lymphocyte 
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Figure 6.19 – Electron micrograph showing urothelial denuding 
(Philips CM120 transmission electron microscope, X8800 magnification, epoxy resin stained slide) 
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Figure 6.20 – Electron micrograph showing basement membrane thickening 
(Philips CM120 transmission electron microscope, X8800 magnification, epoxy resin stained slide) 
Basement membrane 
thickening 
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CHAPTER 7  
DISCUSSION 
Each result is discussed individually. 
 
7.1   Giemsa Stain 
A vital step in the sequence leading to the diagnosis of symptoms of overactive bladder 
(OAB) is the exclusion of urinary tract infection (UTI). A number of recent publications have 
cast doubt on the veracity of normal midstream urine (MSU) culture and urinary dipstick 
analysis for accomplishing this step. Since 1968 it has been known that the best surrogate 
method of diagnosing urine infection, in symptomatic patients, is the identification of pyuria 
of ≥10 wbc μl-1, counted by microscopic examination of fresh unspun urine in a 
haemocytometer. This has been validated in patients with very clear acute urinary tract 
infection. As mentioned earlier, the threshold of pyuria has not been tested in OAB patients 
and hence in this study the pyuria was taken as ≥1 wbc μl-1 because there was no data to 
justify ≥10 wbc μl-1 as a threshold in this clinical context and hence it seemed wisest to stick 
to a clear dichotomy of zero pyuria or some. 
 
Being laborious and requiring certain skills, fresh urine microscopy is not a usual method for 
screening patients with OAB symptoms. Nevertheless, it has been reported elsewhere that 
new patients presenting with OAB symptoms manifest pyuria ≥1 wbc μl-1 34% of the time 
(95% CI 32% to 37%) with only 35% of these proving MSU culture positive at 10
5
 colony 
forming units (cfu) ml
-1
 ( 95% CI 29% to 41%). Asymptomatic controls showed pyuria ≥1 
wbc μl-1 7% of the time (95% CI 1% to 14%)(178). These data imply that a third of patients 
with OAB symptoms exhibit microscopic pyuria ≥1 wbc μl-1 and two thirds of these are 
routine culture negative. 
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In focusing on this study; there are several options available for elucidating the nature of this 
phenomenon. A basic first step would be a morphological description of the inflammatory 
exudate that is implied by the pus cells in the urine. It would be important to confirm that the 
pyuria ≥1 wbc μl-1 does originate from the bladder. Another consideration is the fact that 
urine output varies and that any inflammatory exudate must be subject to dilution of lesser or 
greater degree. The morphology of the exudate can be addressed by using stains to achieve 
differential cell analysis. The bladder origin can be ensured by sampling through a catheter. 
The effect of dilution can be countered by centrifuging the samples and as all these urine 
samples were collected in the morning, the effect of variation on urinary dilution was kept to 
the minimum. 
 
These data used CSU or meticulous MSU so the probability that the urinary cell content 
originated from the bladder was very high. The data collected for this study reconfirmed the 
previous identification of pyuria ≥1 wbc μl-1 in 34% to 48% of OAB patients. None of the 
controls showed pyuria in this study. 
 
The preparation of spun urinary sediments successfully achieved concentrated samples that 
nevertheless exhibited some quantitative properties. The Giemsa stain proved successful in 
permitting a differential analysis of the morphology of white cells in the urinary sediment by 
discriminating lymphocytes and polymorphonuclear leucocytes. This process has unearthed 
evidence of a vigorous urothelial inflammatory cell response in patients with OAB symptoms, 
whether exhibiting pyuria ≥1 wbc μl-1 or not. Pyuria ≥1 wbc μl-1 if present was associated 
with an increased inflammation with numerous acute inflammatory cells with 
lymphocyte:neutrophil ratio of 2:3 whereas patients with OAB symptoms zero pyuria appears 
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to be associated with a balanced mixed acute and chronic inflammation manifest by 
lymphocyte:neutrophil ratio of 1:1. 
 
The use of Giemsa stain for differential counting of urinary sediment has not been previously 
reported. It is commonly used for differential white cell analysis of blood films. Whilst this 
was a novel approach it did prove to be most satisfactory in achieving the morphological 
analysis that was sought.  
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7.2   Histology 
In recent years there has been an increased interest in the role of the urothelium in the 
pathophysiology of overactive bladder (OAB) (182). This has included a focus on afferent 
nerves and the influence of adenosine triphosphate (ATP) on puringergic receptors. Data 
from human experiments are limited but increase of stretch activated release of ATP from 
bladder urothelial cells in patients with interstitial cystitis has been described (183). A human 
urothelial pathology associated with OAB symptoms has not been rigorously defined. Animal 
models have shown increased urothelial ATP release in association with inflammation (184) . 
One mechanism underlying OAB could be a chronic urothelial stress and inflammation 
resulting in excessive release of ATP. It was reasonable therefore to respond to the 
inflammatory exudate identified in the urinary sediment by scrutinising the urothelium for 
evidence of an inflammatory response 
   
Whilst the physiological literature in this arena has been growing there is a striking lack of a 
histopathological data. This experiment scrutinised urothelial histology in patients with OAB 
symptoms without pyuria, a sterile urine and who required maximum anticholinergic therapy. 
Another group of OAB patients with recalcitrant pyuria ≥1 wbc μl-1 were also examined. A 
very small number of normal controls (total 5 – all males) were achieved because of the 
difficulty of obtaining biopsies from such persons. 
 
The histological features seen under the light microscope were supportive of the findings in 
the urinary sediments of patients with OAB whether they had pyuria ≥1 wbc μl-1 or not. The 
morphological changes implied chronic inflammatory activity that had resulted in urothelial 
hyperplasia and metaplasia, urothelial denuding, oedema and congestion, and mixed 
inflammatory cell infiltrate. The normal urothelium is devoid of any of these features 
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described. The original purpose of this analysis was to test the veracity of the observation of 
pyuria ≥1 wbc μl-1 in a significant minority of patients with OAB. The Giemsa staining of 
spun urinary sediments was to serve a similar purpose. It was a surprise of both experiments 
to find clear evidence of urothelial inflammation, not only in OAB patients with pyuria ≥1 
wbc μl-1 but those without pyuria. These findings raise the important question as to whether 
OAB is in fact a manifestation of chronic cystitis that goes undiagnosed by conventional 
methods. Whether this cystitis is due to urinary tract infection has not been a subject for this 
thesis. However, it has to be accepted that infection, bacterial or otherwise, must remain a 
suspect. In the introduction it has been described about the considerable doubts that must 
affect the routine methods used to exclude urine infection. The data obtained in this project 
would surely justify a very thorough exploration of urinary infection in this context. The ICS 
definition of OAB, assumes the exclusion of urinary infection by dipstick or urine culture. 
The literature indicates that this is included in the definition because excluding infection, 
amenable to antibiotic treatment, would be a wise precaution. It is not based on a body of 
evidence that has been gleaned from a careful, critical study of the culpability of bacterial 
UTI in the generation of the symptoms or pathophysiology of OAB. 
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7.3  Pap Stain 
The Pap stain experiment was deployed as a falsification exercise. This implies that the 
excessive shedding of the urothelial cells doesn’t happen in state of chronic stress. We know 
that epithelia that experience the assault of chronic inflammation will invariably respond by 
metaplastic changes. The story of pyuria ≥1 wbc μl-1 in patients with OAB and current 
evidence pointed to a chronic cystitis as one plausible explanation. If that were to be true it 
should be expected that evidence of metaplasia should be forthcoming. The urinary spun 
sediment prepared from a CSU using a Cytospin when stained by the Pap method provides 
excellent information on the morphology of the urothelial cells. If metaplasia were affecting 
the urothelium it should be expected to be revealed by an increase in surface cell shedding, 
increased immature transitional cells and squamous metaplasia. If that was not found it would 
go a substantial way to refute the hypothesis of chronic cystitis associated with pyuria ≥1 wbc 
μl-1 in OAB. 
 
The data demonstrated that OAB with or without pyuria was associated with increased cell 
shedding with increased numbers of immature transitional cells and superficial umbrella cells. 
There was no difference in the numbers of squamous cells identified between the groups. 
There are several explanations for this. The first is the fact that sampling by CSU from 
normal controls proved very difficult and as a result had to be forced to use MSU, albeit 
collected with much care. Nevertheless, the probability of contamination by skin cells was 
high. Regrettably the number of CSU samples from controls was too small to permit a valid 
comparison. The second explanation could be that the normal controls had squamous 
metaplasia in their bladders. A macroscopic cystoscopic finding that is commonly described 
is squamous metaplasia of the trigone which might account for this. This appears as a pearly 
white carpet at the bladder base which was definitely not seen in the five normal controls who 
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contributed to this study by cystoscopy and biopsy. The third possibility is that there was 
some error in the method. This could also be attributed to difference in age, sex and 
compounding factors but that would act more as a limiting factor that prevented from getting 
the desired result. This has been mentioned in the limitation of the study. 
 
There was an increased shedding of deep transitional cells in OAB groups when compared 
with normal controls. This does imply the increased cell turnover of deeper immature cells 
which would imply chronic urothelial stress. The differences in number of umbrella cells 
shed were small because these proved to be comparatively rare in the sediments.  
 
The Pap stain result failed to refute the hypothesis of chronic urothelial stress. This 
experiment lacked some teeth because majority of MSU samples had to be used from the 
control subjects and that opened the samples to contamination from squamous cells outside 
the urinary tract. It would be extremely useful for this experiment to be repeated in 
circumstances where CSU samples could be collected from normal asymptomatic controls. A 
possible source would be patients undergoing an operative procedure that required bladder 
catheterisation whilst urinary symptoms did not feature in the clinical story. It may also be 
wiser to loosen the recruitment criteria for controls as this may have been misguided in 
setting very stringent criteria for this study. 
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7.4   Electron Microscopy 
Electron microscopy is a method for assessing the ultrastructure of the urothelium. At the 
outset it was not sure what this method was likely to show and had to be approached without 
preconceptions. The key finding was to be able to identify the inflammatory changes that had 
been seen on light microscopy. The denuding of the urothelium was well shown and the 
changes implied that there must be some breakdown in the adhesion molecules that would 
normally bind the urothelial cells to the basement membrane. In all cases where denudation 
was apparent the fracture occurred at the basement membrane. An interesting feature was the 
thickening of the basement membrane. At first site it just seemed to be thicker than 
comparative images from EM texts and the BM of other epithelia. Proper control comparison 
was essential but hampered by the paucity of such samples.  However, in situations where the 
membrane was irregular in controls and patients the dimensions of the OAB basement 
membrane were sufficiently increased to show a significant difference from a very small 
control sample (male only). It would be wrong to infer too much from this observation and 
the best option would be to repeat the experiment with some comparative controls, perhaps 
selected on less rigorous criteria, and mixed gender. The finding of basement membrane 
thickening is well documented in patients with Interstitial cystitis (IC) (185).  
 
Haferkamp A et al. and Resnick NM et al. have done extensive electron microscopic studies 
on detrusor muscle in neurogenic bladder dysfunction but it was not focused on urothelium 
and basement membrane and certainly did not involve patients with OAB symptoms (186-
188).  
 
The literature search failed to locate any publications reporting similar studies of the 
basement membrane in OAB.  
 152 
7.5   Limitations of the Study 
There are a number of limitations that must be acknowledged for this study.  
The sample selection could not be randomised, had it been done the study would have been 
unable to achieve the sample sizes that were needed.  
 
There was some overlap between the patients who provided samples for Giemsa and for Pap. 
Had time and patient numbers permitted it would have been attractive to have studied 
different samples from the representative groups. In all circumstances it was possible to 
maintain a blind over the identity and clinical situation as it affected the patients or controls. 
 
The greatest proportion of OAB patients donating bladder biopsies were on anticholinergic 
therapy and had not responded, to the extent that they required Botox injections. This means 
that they are a selected group but their symptoms and clinical state re extremely well 
characterised. It would be a much harder option to seek to effect cystoscopies and biopsies 
from patients with less troublesome OAB. Let’s hope that the development of the methods of 
scrutinising urinary spun sediments may make this unnecessary. 
 
It was not possible to match the OAB patients with normal controls in terms of age, sex and 
menopausal status. The controls were mostly men, younger and in the main they provided 
MSU’s. As the screening criteria were very stringent, particularly the requirement for there to 
be no nocturia, it was very difficult to find matched asymptomatic normal controls. On a 
brighter note, the controls were extremely normal persons. It was an extremely hard work to 
recruit asymptomatic normal controls willing to provide CSU samples but that was also very  
difficult task which was managed in a very few circumstances in the operating theatres.  
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The greatest difficulty of all was to recruit asymptomatic normal controls for bladder biopsy. 
This group was recruited from persons undergoing routine cystoscopy so finding individuals 
without any urinary tract symptoms was a challenge. Such patients were few and far between 
and all of them were young, unsurprisingly.  
 
For methods involving urine Cytospin™ preparations, staining and reading slides, It would 
have been useful to have been able to use a standardised counting method but it transpired 
that such a method had not previously been scribed. At first, the first 100 cells were counted 
and calculated the relative expression of different cell types. It then became evident that the 
Cytospin deposit provided a semi-quantitative field and in order to take advantage of this, re-
counting of the whole cell set in each preparation was effected. 
 
It would have been preferred to have prepared own tissue samples for histology and electron 
microscopy. However, It had to accept that it was dealing with material from patients and that 
the findings could have clinical implications. The researcher did not have the practiced skills 
of NHS laboratory technicians and the hosting departments felt that it was imperative that 
such slides be prepared by certified personnel. Nevertheless the researcher certainly learned 
the methods and could achieve the requisite preparations although at this time they would be 
of an inferior quality to those produced by experienced laboratory staff. 
 
When it came to analysing the prepared slides for Pap and Giemsa stain, lot of difficulty was 
encountered before managing to achieve the desired results. It was imperative to be able to 
identify the cells correctly because it was needed to achieve the quantitative analysis. It all 
started by comparing the  cells under the microscope to follow photomicrographs in a  
reference Atlas of cytology but this proved far more difficult than at face value as the Atlas 
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photomicrographs were evidently ideal examples. Therefore a formal training was arranged 
during five sessions under the supervision of a consultant histopathologist at UCL hospital. 
She eventually assessed the ability and passed the researcher having sufficiently skilled to 
assess the samples necessary, given the scope of this project. As audit, cross-checking with 
her a number of findings during the course of the project were carried out. It should be noted 
that there is certainly a skill component to this type of work and that is not easy to quantify in 
arid scientific terms. 
 
There were similarly difficulties during analysing and reading the histology slides. It was 
found that picking out different features with confidence was indeed difficult. The atlas and 
textbooks are less helpful than would be expected because of the excellent quality of the 
illustrations that are shown. The supervisor went through the basics of reading histology 
slides so as to build the initial confidence. Thereafter, eight sessions were arranged with the 
consultant histopathologist at the UCL hospital who once again trained and assessed the 
capacity of the researcher to handle the demands of this project. She cross-checked all of the 
histopathology slides that were interpreted by the researcher as did a second histopathologist 
at the Whittington Hospital. 
 
Finally, learning to interpret EM micrographs was similarly challenging but the provision of 
the excellent support from the electron microscopist at the Royal Free Hospital came into 
good stead. The basement membrane was measured together by the researcher and the 
electron microscopist and despite the vast experience of the electron microscopist it was 
difficult at times to assess and measure the basement membrane thickness. The potential for 
errors was reduced by the large number of measurements taken. 
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CHAPTER 8 
CONCLUSION 
 
This study shows evidence of chronic cystitis and urothelial hyperplasia associated with OAB 
irrespective of pyuria. This has been scrutinised by three different methods. The very fact that 
the urine was processed and stained with Giemsa stain and to get the tissue biopsy to undergo 
the H & E stained histopathological analysis with further unearthing of the ultrastructural 
changes with the help of epoxy resin stained electron microscopy, and all to show the 
inflammatory changes it certainly cements the fact that the inflammation/infection lies at the 
heart of overactive bladder. The routine screening for the exclusion of UTI in patients 
presenting with symptoms of OAB  need to be revisited. 
 
Further studies with large cohort of patients, with matched patients and control, need to be 
carried out. 
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CHAPTER 9 
FUTURE WORK 
 
There has been some very excising proposal and ongoing projects being carried out in 
relation to further the work on inflammation, with regards to OAB. The Interleukin 6 assay 
on urine sample and comparing it with different markers of inflammation has been going on. 
The use of Sternheimer-malbin stain and comparing it with various stains to enhance the 
pickup rate of the leucocytes, along with comparing the decay of leucocytes/pyuria in urine 
sample subjected to temperature change, delay in processing the urine in laboratory and use 
of different preservatives, is an ongoing work. There is further work in relation to finding the 
intracellular bacterial colonies from urine culture and bladder biopsy is being carried out. 
Further work related to enhance ATP secretion and use of Scanning Electron Microscopy on 
the Urothelial cells is going on.   
 
The current project on urinary Lactoferrin holds good promise for the future as a surrogate 
marker of infection. 
 
The role of long term antibiotics and whether or not one shot of intravenous antibiotics in 
patients with symptoms of OAB, presenting with pyuria but urine culture negative, is to be 
presented to the Ethical committee to set it up as a pilot project. 
 
In essence, there has been lot of exciting prospect and projects going on to enhance our 
understanding with regards to inflammation especially in patients with symptoms of OAB. 
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CHAPTER 10 
 
STUDY DOCUMENTS 
 
10.1   Appendix 1 
Flexible cystoscopy  
• Here, we explain some of the aims, benefits, risks and alternatives (including no treatment) 
to this procedure. You will also receive a separate clinic information sheet. We want you to 
be informed about your choices to help you to be fully involved in making any decisions.  
• Please ask about anything you do not fully understand or wish to have explained in more 
detail.  
• If you would like this information in another format or language or would like help 
completing the form, please ask a member of our staff.  
 
Intended benefits of the procedure  
To find the cause of the bladder symptoms or to check that the bladder is clear of disease. 
 
Who will perform my procedure?  
A doctor trained in urology, surgery of the bladder, will perform the procedure.  
 
The procedure: 
A doctor will insert an instrument called a cystoscope (very fine and soft telescopic tube) into 
your bladder via the water pipe (urethra). Attached to the instrument are a telescopic lens, a 
light source and some sterile water to fill the bladder so that the lining can be inspected. A 
local anaesthetic gel is used to numb and lubricate the urethra to make the passage into the 
bladder as comfortable as possible.  
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Some patients may experience slight discomfort during the procedure but the majority do not. 
If you do feel uncomfortable at any time you should inform the doctor performing the 
examination immediately.  
 
Once the instrument is in place, the examination will take only a few minutes to complete.  
 
Once the inspection is completed, the instrument will be removed, and you will be informed 
of the findings and the need for any further management.  
  
A nurse will remain with you whilst the treatment is taking place and will explain anything 
you do not understand.  
 
Alternative procedures that are available  
The alternative is to have a cystoscopy under a general anaesthetic. 
 
Serious or frequently occurring risks  
There are potential complications with any procedure. Although these are rare, it is important 
that you are aware of them and have the opportunity to discuss them with your doctor.  
 
Common  
Mild burning or bleeding on passing urine for a short period after the Operation.  
 
Occasional  
Infection of the bladder requiring antibiotics. We shall be giving you a course of antibiotic 
treatment lasting one day at the time of the procedure 
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Rare  
Delayed bleeding requiring removal of clots or further surgery.  
Injury to the urethra causing delayed scar formation.  
Difficulties in passing urine after the procedure requiring temporary insertion of a catheter.  
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10.2   Appendix 2 
Bladder biopsy via cystoscopy 
A study of bladder tissue sample and patient symptoms 
 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time to 
read the following information carefully and discuss it with friends, relatives and your GP if 
you wish. Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and 
You’. This leaflet gives you more information about medical research and looks at some 
questions you may want to ask. A copy may be obtained from CERES, PO Box 1365, 
London N16 OBW. CERES also has an excellent Website, which contains much advice and 
information about research (http://www.ceres.org.uk/). You may also obtain information 
from the hospital Patient Advice and Liaison Service (PALS), Whittington Hospital, Tel 020 
7288 5956 or 020 7288 5957 
 
Thank you for taking the time to read this information and for considering helping us with 
our research project. 
 
What is the purpose of the project? 
Many people suffer with Overactive Bladder symptoms and urinary incontinence (leaking 
from the bladder). It is a very unpleasant problem that affects people’s lives at home, at work 
and their general well-being. The aim of this study is to examine urine and samples of the 
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bladder tissue to better understand how the bladder works and relate these findings to patient 
symptoms. 
 
Why have I been chosen? 
You have been chosen because you have the symptoms of an overactive bladder. 
Alternatively you are without lower urinary tract symptoms but are scheduled to have a 
routine cystoscopy. The cystoscopy procedure is described in the attached leaflet. This test 
provides an opportunity to take a sample (biopsy) from your bladder. We should like to do 
this so as to use the sample for research purposes. 
 
Do I have to take part? 
It is up to you if you decide whether or not to take part. If you do decide to take part you will 
be given a copy of this information sheet to keep. You will be asked to sign a consent form a 
copy of which will be given to you. If you decide to take part you are still free to withdraw at 
any time and without giving a reason. This will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
If you decide to take part in the project the research clinician will arrange to see you. You 
will be asked some questions about your bladder and how well it works for you. Your 
answers will be recorded on a form stored on a computer. This will take about 30-45 minutes. 
The computer record is closely guarded by the NHS security system so there is no 
unauthorised access to you record. Blood samples may or may not be taken as part of your 
normal clinical care. We should like to record the results of these in your research record. A 
random code will decide whether you will undergo the flexible cystoscopy procedure or not, 
despite your consent to be a part of the study. 
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When you have the cystoscopy the doctor will take a very small sample of bladder tissue 
(about 1-2mm) in addition to any that may be needed as part of your normal clinical care. 
 
What will be done with the biopsy tissue that is taken for this study? 
The tissue sample taken at biopsy from the bladder will be studied in detail with various 
staining methods and under a special microscope. The use of your specimen, where it goes, 
and the results of any experiments that are conducted on it, will be kept on the record and 
could be made available to you should you so wish. In effect there will be the full story of 
your specimen. 
 
What are the alternatives to participating in the study? 
It is entirely your decision if you wish to take part in the study and it will not affect your 
future care if you do not wish to do so. If you do not wish to take part you will have your 
assessment in the usual way. If a cystoscopy would be a normal part of your clinical care, this 
will happen in the usual way.  
 
What are the possible disadvantages and risks of taking part? 
With each bladder biopsy there is a small amount of bleeding, but this will usually stop after 
a day or so. This will be manifest as a pink colour to your urine, which rapidly clears. 
 
There is a risk of cystitis but we shall cover you for this by administering a single dose of an 
antibiotic at the time of the procedure. 
What are the possible benefits of taking part? 
The sample of bladder tissue taken for this research will be considered as a ‘gift’ to the 
university and after the research has been completed the sample will be destroyed. There are 
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no benefits directly to you for taking part. But your participation will help us to have a better 
understanding of how the bladder works and may lead to better treatments being available to 
people with bladder problems in the future.  
 
What happens if something goes wrong? 
If taking part in this research project harms you, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have grounds 
for legal action but you may have to pay for it. Regardless of this, if you wish to complain 
about any aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms will be available to you. 
 
What if I want to withdraw from the study? 
You are free to withdraw from the study at any time before and after signing the consent form 
without needing to give any explanations. If you wish to withdraw after the bladder sample 
has been taken then you may contact us and we will not use the sample for any experiments. 
 
Will my taking part in this study be kept confidential? 
All information, which is collected about you, during the course of the research, will be kept 
strictly confidential. Any information about you which leaves the hospital / surgery will have 
your name and address removed so that you cannot be recognised from it. 
 
Your GP will be notified of your involvement in the study unless you do not wish us to do so. 
What will happen to the results of the research? 
The results of the experiments made on the samples of bladder tissue will be published in 
scientific journals so that other researchers working on improving treatments for people with 
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troublesome bladder symptoms and incontinence will benefit from this knowledge. You will 
not be identified of any publications. 
 
Who is organising and funding the research? 
This study is organised by the Department of Medicine at the Whittington Hospital. 
 
Who has reviewed the study? 
The East London Research Ethics Committee has reviewed this study. 
 
Contact for further information 
If you have any questions please don’t hesitate to contact us. 
 
Professor James Malone-Lee MD FRCP 
Professor of Medicine 
The Department of Medicine,  
Clerkenwell Building,  
Whittington Hospital,  
Archway Campus,  
Highgate Hill,  
London, N19 5LW 
Telephone  0207 288 3010 
  0207 288 3135 
  0207 679 9112 
  0207 288 5301 
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10.3   Appendix 3 
A study of bladder tissue and patient symptoms 
Consent Form  
Confidential 
Investigator’s name:      _____________________________ 
 
                 To be completed by the participant   
Have you read the information sheet about this study? Yes                    No 
Have you had an opportunity to ask questions and discuss this 
study? 
Yes                    No 
Have you received satisfactory answers to all your questions? Yes                    No 
Have you received satisfactory answers to all your questions? Yes                    No 
Have you received enough information about this study? Yes                    No 
Which staff member did you speak to about this study? Yes                    No 
Do you understand that you are free to withdraw from this 
study, at any time, without giving a reason for withdrawing and 
without it affecting your future medical care? 
Yes                    No 
Do you understand that you will not benefit financially if the 
research leads to the development of a new treatment or medical 
test 
Yes                    No 
Do you understand that you will not benefit financially if the 
research leads to the development of a new treatment or medical 
test? 
Yes                    No 
May we contact your GP to inform him/her that you wish to Yes                    No 
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take part in this study?  
Do you agree to enter this study? Yes                    No 
 
 
__________________ ______________________________  ___________ 
Signature (Participant)  Print name       Date    
 
______________________ ______________________________  ___________ 
Investigator’s signature  Print name       Date 
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10.4   Appendix 4 
Bladder  symptom questionnaire 
Date of birth……….                  Sex   F / M…………… 
Study number………………………………………… 
Date………………………………. 
        None  Some Much 
 
           
Do you experience urgency? That is having 
to hurry in order to pass urine?      1 
 
Do you experience urge incontinence? That 
is hurrying to pass urine and not making 
it in time?        2 
 
Does cold weather make your bladder 
symptoms worse?       3 
 
Do you find that running water from  
a tap causes urinary urgency or 
incontinence?        4 
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Do you find that putting a key in the 
front door when returning home  
causes urinary urgency or  
incontinence?        5 
 
Do you find that on getting up from 
bed in the morning you experience  
urgency or urge incontinence?     6 
 
Is there any pain associated with 
the urgency?         7 
 
Do you ever leak urine on 
coughing, sneezing, running, 
laughing, lifting?       8 
 172 
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